

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The efficacy and safety of varenicline alone versus in combination with nicotine lozenges for smoking cessation among hospitalised smokers (VANISH): study protocol for a randomised, placebo-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038184
Article Type:	Protocol
Date Submitted by the Author:	02-Mar-2020
Complete List of Authors:	Gobarani, Rukshar; Monash University - Parkville Campus, Centre for Medicine Use and Safety Abramson, Michael; Monash University, Dept of Epidemiology and Preventive Medicine Bonevski, Billie; University of Newcastle, School of Medicine & Public Health Weeks, Gregory; Barwon Health Dooley, Michael; Monash University, Centre for Medicine Use and Safety; The Alfred, Pharmacy Department Smith, Brian; Bendigo Health - Bendigo Hospital Campus, Department of Clinical Epidemiology and Biostatistics Veale, Antony; The Queen Elizabeth Hospital, Department of Respiratory Medicine Webb, Ashley; Frankston Hospital, Department of Anaesthesia and Pain Management Kirsas, Sue; Monash Health, Pharmacy Thomas, Dennis; The University of Newcastle Hunter Medical Research Institute, Priority Research Centre for Healthy Lungs Miller, Alistair; Monash Health, General Medicine Unit and Monash Lung and Sleep Department Gasser, Rudi; Barwon Health, Department of General Medicine Paul, Eldho; Monash University, School of Public Health and Preventive Medicine; Alfred Health, Clinical Haematology Department Parkinson, Jacqueline; Monash Health, Pharmacy Meanger, Darshana; Frankston Hospital, Pharmacy Coward, Lisa; Frankston Hospital, Anaesthesia Kopsaftis, Zoe; The Queen Elizabeth Hospital, Respiratory Medicine and Clinical Practice Unit Rofe, Olivia; Eastern Health Foundation, Pharmacy Lee, Paula; Eastern Health Foundation, Pharmacy George, Johnson; Monash University, Centre for Medicine Use and Safety
Keywords:	PUBLIC HEALTH, Clinical trials < THERAPEUTICS, PRIMARY CARE



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open: first published as 10.1136/bmjopen-2020-038184 on 6 October 2020. Downloaded from <http://bmjopen.bmj.com/> on April 17, 2024 by guest. Protected by copyright.



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

2
3 **The efficacy and safety of varenicline alone versus in combination with nicotine**
4 **lozenges for smoking cessation among hospitalised smokers (VANISH): study protocol**
5 **for a randomised, placebo-controlled trial**
6
7
8

9
10 Authors:

11
12 **Miss Rukshar K. Gobarani**, BPharm (Hons), Centre for Medicine Use and Safety, Monash
13 University, Parkville, Victoria, Australia; rukshar.gobarani@monash.edu
14

15
16 **Prof Michael J. Abramson**, PhD, FRACP, School of Public Health and Preventive
17 Medicine, Monash University, Melbourne, Victoria, Australia;
18
19 michael.abramson@monash.edu
20
21

22
23 **Prof Billie Bonevski**, PhD, School and Medicine and Public Health, University of
24 Newcastle, Callaghan, New South Wales, Australia; billie.bonevski@newcastle.edu.au
25
26

27
28 **Dr Gregory R. Weeks**, PhD, Pharmacy Department, Barwon Health, Geelong, Victoria,
29 Australia; greg@barwonhealth.org.au
30
31

32
33 **Prof Michael J. Dooley**, PhD, Centre for Medicine Use and Safety, Monash University,
34 Parkville, Victoria, Australia; Pharmacy Department, The Alfred, Prahran, Victoria,
35 Australia; M.Dooley@alfred.org.au
36
37

38
39 **Prof Brian J. Smith**, MBBS, FRACP, PhD, Dip Clin Epi and Biostats, Bendigo Hospital,
40 Victoria, Australia; bsmith555@bigpond.com
41
42

43
44 **Dr Antony Veale**, MBBS, FRACP, Department of Respiratory Medicine, The Queen
45 Elizabeth Hospital, Adelaide, Australia; antony.veale@sa.gov.au
46
47

48
49 **Dr Ashley Webb**, MBBS (Hons), MPH, FANZCA Department of Anaesthesia and Pain
50 Management, Peninsula Health, Frankston, Victoria, Australia; AWebb@phcn.vic.gov.au
51
52

53
54 **A/Prof Sue Kirsa**, Grad Dip Hosp Pharm, Pharmacy Department, Monash Health, Clayton,
55 Victoria, Australia; Sue.Kirsa@monash.edu
56
57

58
59
60
02/03/2020 V5

2

Dr Dennis Thomas, PhD, Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, University of Newcastle, New South Wales, Australia;

dennis.thomas@newcastle.edu.au

Dr Alistair Miller, MBBS, General Medicine Unit and Monash Lung and Sleep Department, Monash Health, Clayton, Victoria, Australia; alistair.miller@monashhealth.org

Dr Rudi Gasser, MBBS, Department of General Medicine, Barwon Health, Geelong, Victoria, Australia; rudig@barwonhealth.org.au

Dr Eldho Paul, PhD, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Clinical Haematology Department, The Alfred, Melbourne, Victoria, Australia; eldho.paul@monash.edu

Ms Jacqueline Parkinson, MPharm, Pharmacy Department, Monash Health, Clayton, Victoria, Australia; Jacqueline.Parkinson@monashhealth.org

Miss Darshana Meanger, BPharm, Grad Cert Pharm Prac, Pharmacy Department, Peninsula Health, Frankston, Victoria, Australia; DMeanger@phcn.vic.gov.au

Ms Lisa Coward, EEN, Department of Anaesthesia, Peninsula Health, Frankston, Victoria, Australia; LCoward@phcn.vic.gov.au

Dr Zoe Kopsaftis, PhD, BHSc (Hons), Respiratory Medicine and Clinical Practice Unit, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Zoe.Kopsaftis@sa.gov.au

Ms Olivia Rofe, BPharm, MPharm (Clin), Prof Cert Health Syst Management, Pharmacy Department, Eastern Health, Melbourne, Victoria, Australia;

Olivia.Rofe@easternhealth.org.au

Ms Paula Lee, BPharm, Grad Dip Clin Res, Pharmacy Department, Eastern Health, Box Hill, Victoria, Australia; Paula.Lee@easternhealth.org.au

Dr Johnson George, PhD, Centre for Medicine Use and Safety, Parkville, Victoria, Australia; johnson.george@monash.edu

02/03/2020 V5

ABSTRACT

Introduction: Smoking is a leading cause of premature deaths globally. The health benefits of smoking cessation are many. However, majority of quit attempts are unsuccessful. One way to potentially improve success rates is to evaluate new combinations of existing smoking cessation therapies that may work synergistically to decrease the intensity of withdrawal symptoms and cravings.

Aims: To evaluate the feasibility, efficacy and safety of the combination of varenicline and nicotine replacement therapy (NRT) lozenges versus varenicline alone in assisting hospitalised smokers to quit.

Methods and analysis: This is a multi-centre, randomised, placebo-controlled trial. Adults with a history of smoking ≥ 10 cigarettes per day on average in the four weeks prior to their hospitalisation will be recruited. Participants will be randomly assigned to either the intervention group and will receive varenicline and NRT lozenges, or the control group and will receive varenicline and placebo lozenges. In addition to this, all participants will be actively referred to behavioural support from telephone Quitline. Participants are followed up at 1 and 3 weeks and 3, 6 and 12 months from the start of treatment. The primary outcome is carbon monoxide (CO) validated continuous abstinence from 2 weeks to 6 months after treatment initiation. Secondary outcomes include self-reported and biochemically validated continuous and point prevalence abstinence at 3, 6 and 12 months, self-reported adverse events, withdrawal symptoms and cravings, adherence to treatment, Quitline sessions attended etc. According to the Russell standard, all randomised participants will be accounted for in the primary intention-to-treat analysis.

Ethics and dissemination: The trial will be conducted in compliance with the protocol, the principles of Good Clinical Practice, the National Health and Medical Research Council

4

(NHMRC) National Statement on Ethical Conduct in Human Research (updated 2015) and the Australian Code for the Responsible Conduct of Research (2018). Approval will be sought from the Human Ethics Committees of all the participating hospitals and the University. Written informed consent will be obtained from each participant at the time of recruitment.

Trial registration: Australia New Zealand Clinical Trials Registry:

ACTRN12618001792213

Strengths and limitations of this study:

- This is the first multi-centre, randomised, placebo-controlled trial to evaluate the efficacy and safety of a combination of varenicline and an immediate-release form of NRT.
- This is also the first pragmatic trial exploring the effectiveness of this combination treatment in achieving long-term abstinence rates among inpatients in Australian hospitals.
- The multi-centre pragmatic design of the trial will ensure that the study sample is representative of the inpatient smokers who are admitted to Australian public hospitals allowing greater generalizability of study findings
- Biochemical verification of abstinence used in this trial will enable us to make accurate inferences regarding the effectiveness of the intervention.

BACKGROUND

Tobacco smoking is one of the leading causes of preventable morbidity and mortality around the world. Representing a key risk factor for deaths due to ischaemic heart disease, stroke and cancer, tobacco smoking kills approximately six million people globally each year (1). Holding the potential to damage nearly every organ system in the human body, tobacco smoking accounts for 7.8% of the total burden of disease in Australia (1, 2). Despite this, 14% of adults aged 18 years and over smoked daily in 2017-2018 (3).

Various therapeutic agents are currently available to assist in quitting smoking. A substantial body of research has demonstrated the effectiveness of such therapies in increasing abstinence rates (4). Of these, varenicline is the most effective single agent for abstinence outcomes. Available as a prescription only medicine in Australia, varenicline at the standard dose more than doubles the chances of quitting compared with placebo (pooled RR for continuous or sustained abstinence at six months or longer 2.24; 95% CI 2.06 to 2.43) (5). It has a dual mechanism of action and exerts its effects by acting as a partial agonist at the $\alpha 4\beta 2$ nicotinic receptors in the brain (6). This reduces the drop in the mesolimbic dopaminergic levels that occurs during smoking cessation, relieving withdrawal symptoms (6). Varenicline also antagonises the activity of nicotine on its receptors which prevents the release of neurotransmitters such as dopamine and in doing so reduces feelings of pleasure experienced from a smoking relapse (6).

Nicotine replacement therapy (NRT) is another first line treatment for those seeking pharmacological help to quitting smoking (4). NRT replaces some of the nicotine in the blood that was previously derived from cigarettes, without the presence of the thousands of other chemicals that are also produced during tobacco combustion which are largely responsible for

6

causing tobacco-related illnesses (7, 8). In this manner, NRT decreases the intensity of withdrawal symptoms and cigarette cravings (7, 8).

In many countries, NRT is available over-the-counter in acute release formulations such as gums, lozenges, inhalers, mouth sprays and sublingual tablets and in slow release forms such as transdermal patches. Transdermal patches release nicotine slowly over a prolonged period of time (24 or 16 hour patches available) whereas, acute release forms of NRT provide a faster release of nicotine in the blood (7). Acute-dosing products allow the user to titrate both the amount and timing of their doses (7). Therefore, these forms of NRT can be used as “rescue-medication” by smokers to alleviate cigarette cravings (7).

NRTs are more effective than placebo in achieving long-term smoking abstinence (RR of abstinence for any form of NRT relative to control 1.55; 95% CI 1.49 to 1.61) (9). Various forms of NRT perform similarly against each other [pooled RRs of 1.64 for nicotine patch (95% CI 1.53 to 1.75); 1.49 for nicotine gum (95% CI 1.40 to 1.60) and 1.52 for oral tablets/lozenges (95% CI 1.32 to 1.74) relative to control], and evidence suggests that the use of two forms of NRT; a slow release formulation with an acute release formulation (i.e. combination NRT) is more effective than using a single form of NRT (9, 10).

Research to date suggests that varenicline (as monotherapy) and combination NRT are the most effective smoking cessation therapies that are currently available to assist in achieving abstinence (4). Even these, however, result in only modest increases in abstinence rates of approximately 30-40% at 6 months compared with placebo (11-15). A substantial amount of research is thus focused on evaluating new treatment options and approaches for smoking cessation to further increase abstinence rates (11).

02/03/2020 V5

7

1
2
3 In attempts to improve smoking cessation rates, new combinations of existing smoking
4 cessation therapies have been evaluated (16-18). Current research suggests that varenicline
5 may not fully saturate the nicotinic acetylcholine receptors in the brain (19). This in turn leads
6 to only a partial attenuation of nicotine cravings (20). It has been postulated that adding NRT
7 to varenicline treatment may therefore increase receptor saturation, which in turn may decrease
8 cigarette cravings more completely (19, 20).
9

10
11
12 In response to this, studies have evaluated the effectiveness of the combination of varenicline
13 and NRT patches versus varenicline monotherapy on smoking cessation rates, although
14 findings have been equivocal (20, 21). A systematic review and meta-analysis of three
15 randomised controlled trials demonstrated that the combination of varenicline and NRT patches
16 was associated with significantly higher rates of abstinence versus varenicline alone at the end
17 of treatment i.e. at 12 weeks (OR 1.50; 95% CI 1.14 to 1.97) and at 6 months (OR 1.62; 95%
18 CI 1.18 to 2.23) (22). This association, however, did not exist when the largest of the three
19 trials, which also used a pre-quit nicotine patch, was excluded from the analysis (22).
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 No studies to date have evaluated the effectiveness of the combination of varenicline and acute
41 release forms of NRT which have proven to be just as effective as NRT patches in assisting
42 smokers to quit (9). Secondly, steady-state plasma varenicline concentrations are achieved after
43 approximately four days of continued treatment (19). During this time, patients may experience
44 significant discomfort from withdrawal symptoms and often continue to smoke for several
45 weeks after initiating varenicline therapy (19). Furthermore, a study reported that while
46 varenicline reduces both tonic and cue-induced cigarette cravings, it does not attenuate cue-
47 induced cravings after stress induction compared to placebo (23). In such situations, the use of
48 an *ad lib* NRT product in combination with varenicline would thus enable patients to better
49
50
51
52
53
54
55
56
57
58
59
60

02/03/2020 V5

8

1
2
3 manage their withdrawal symptoms and cravings particularly to prevent stress and cue-related
4
5 reinstatement of smoking (19, 23).
6
7
8
9

10 Smoking inside public hospitals and within 4 meters of the entrances to all public hospitals is
11
12 prohibited in Australia (24). This restriction provides a window of opportunity for the
13
14 implementation of smoking cessation interventions as inpatient smokers are placed away from
15
16 their usual environmental triggers of smoking (25). During this time of increased vulnerability
17
18 regarding their health, patients may be more motivated to quit and may also be more receptive
19
20 to smoking cessation interventions and a change in behaviour particularly if they are presenting
21
22 with conditions that may be caused or exacerbated by smoking (26-30).
23
24
25
26
27

28 Furthermore, hospitalised inpatients generally smoke a greater number of cigarettes per day
29
30 than the general population and have a higher level of nicotine dependence (1, 31). Varenicline
31
32 is a smoking cessation agent that is targeted towards moderate to heavy smokers (32-34).
33
34 Therefore, this group of patients provide an ideal study population for evaluating the efficacy
35
36 and safety of the combination of varenicline and nicotine lozenges for smoking cessation. In
37
38 addition to this, an inpatient setting allows the trial medications to be commenced and
39
40 administered under clinical supervision of hospital staff. This would ensure that participants
41
42 have immediate access to a healthcare professional for medication education or management
43
44 of an adverse drug event due to any trial medication. This study, therefore, aims to evaluate the
45
46 effectiveness and safety of the combination of varenicline and NRT lozenges versus varenicline
47
48 monotherapy in assisting hospitalised smokers in quitting.
49
50
51
52
53
54

55 **Objectives**

56
57
58
59
60

02/03/2020 V5

9

The primary objective of the study is to compare biochemically-verified continuous abstinence at 6 months in hospitalised smokers treated using varenicline plus NRT lozenges with those treated with varenicline and placebo lozenges.

The secondary objectives of this study are to compare:

- CO verified continuous abstinence from 2 weeks to 12 months after treatment initiation for participants who self-report abstinence at the 12-month follow-up
- Self-reported 7-day point prevalence abstinence and continuous abstinence measured from 2 weeks to 3, 6 and 12 months after treatment initiation
- CO verified 7-day point prevalence abstinence from 2 weeks to 6 and 12 months after treatment initiation for participants who self-report abstinence at these follow-ups
- Self-reported treatment adherence and adverse events to the study medicines at all follow-ups as well as number of Quitline sessions attended after treatment initiation.

METHODS

Study design

A randomised, placebo-controlled, multi-centre, double blinded study

Setting and Participants

Participants will be recruited from the inpatient wards of five 'smoke-free' public hospitals in Australia. Participants will be screened for eligibility at baseline and written informed consent will be sought. Eligible participants will be randomised to either the intervention or control group and will be followed up for 12 months from treatment initiation.

Inclusion and Exclusion criteria

02/03/2020 V5

10

1
2
3 Patients eligible for the trial are: adults ≥ 18 years, admitted to participating hospitals with a
4 history of smoking ≥ 10 cigarettes per day on average in the four weeks prior to their hospital
5 admission, interested in quitting smoking, willing to use pharmacotherapy, available for a 12
6 months follow-up post-treatment initiation and willing/capable to provide written informed
7 consent.
8
9

10
11
12
13
14
15
16
17 Patients who do not meet all of the above inclusion criteria, those who have a terminal illness
18 with an anticipated survival of < 6 months, those who have an unstable cardiovascular status
19 (recent myocardial infarction or stroke within the past 3 months) or those with a new diagnosis
20 of a major psychiatric illness (e.g. psychosis) within the past 3 months will be excluded from
21 the study. Patients unable to communicate in English and provide written consent will also be
22 excluded given the potential need to regularly communicate with the investigators during the
23 entire trial period, and the lack of funding for interpreters.
24
25
26
27
28
29
30
31
32
33

34
35 Further exclusion criteria for this study are: women who are pregnant, breastfeeding or
36 planning to become pregnant in the next 6 months and patients who were already using
37 smoking cessation medications or approaches at the time of their hospital admission (i.e. NRT,
38 varenicline, bupropion, clonidine, nortriptyline, or electronic nicotine delivering systems). In
39 addition to this, patients who are currently participating in other smoking cessation
40 programs/studies, those who have completed ≥ 12 weeks course of varenicline in the 12 months
41 prior to hospitalisation (these patients may have a higher nicotine dependence and may not
42 respond well to sole varenicline therapy), those who have had intolerable/serious adverse
43 events from the use of varenicline or NRTs in the past, and those who have contraindications
44 for their use (including those using medications known to have major interactions with either
45 varenicline or NRT) will be excluded from the study.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

02/03/2020 V5

Participant recruitment

Eligible participants will be identified through active screening of hospital records by a trained Research Assistant (RA), a nurse or a pharmacist employed at each site. Ward staff including doctors, nurses, pharmacists and physiotherapists will be informed of the study and asked to refer all patients identified as current smokers to the RA. Flyers containing study information will be displayed in hospital wards to notify inpatients of the study. Flyers will contain the contact information of the RA at the site so that interested patients can discuss the study with them.

Once potential participants are identified, the RA in consultation with the treating medical team will assess each patient's eligibility for the study considering their current health status and any apparent contraindications for the use of varenicline or NRT. Details of this initial medical screening will be recorded by the RA. The RA will then approach eligible patients, describe the project to each potential participant, provide a plain language statement and answer any questions. If the patient is interested in participating, written informed consent will be sought before proceeding with the baseline interview.

Baseline data collection

Each participant will be assigned a study number and baseline data collected. Data gathered during the interview will include information on the participant's smoking habits, previous attempts at quitting and current willingness/confidence to quit. A detailed medical history (current medical conditions and medications) including the presence of any contraindications or precautions for the use of the study medicines (based on the Product Information Sheets) will be sought. Participants with any exclusion criterion will not be enrolled, and will be

12

referred to Quitline for smoking cessation support. Participants who do not meet any of the exclusion criteria, but who have a cautionary condition, will be referred to an in-house clinician for further assessment. The decision on whether to include such participants will be at the discretion of the treating medical team, the RA and the patient based on an evaluation of the potential risks and benefits from participation in the study.

The baseline interview will also involve an assessment of the presence of psychological distress using the Patient Health Questionnaire (PHQ-9). Once baseline data collection is completed, to ensure the safe ongoing delivery of healthcare services to participants, the RA will seek the participants' consent to contact their regular general practitioner (GP) and community pharmacist to inform them of their patient's participation in the study.

Randomisation: allocation concealment and sequence generation

Following the collection of baseline data, participants will be randomised to one of the study arms by a clinical trials pharmacist at each of the five hospitals using a computer-generated randomisation list. Randomisation is stratified by site and random permuted block sizes of two and four will be used. Sealed opaque envelopes will be used for the concealment of treatment allocation. Each site will be provided with 64 envelopes containing group allocation. The clinical trials pharmacist at each site will open the envelopes in a sequential manner when a participant is recruited to identify group allocation. Once a participant's group allocation has been noted along with the study ID, study medicines will be charted on the participant's medication chart by a clinician involved in the study. The pharmacist will then dispense the study medicines as stated in the envelope ([varenicline and NRT lozenges] or [varenicline and placebo lozenges]) and hand these to the RA along with the envelope. The RA will then give the medicines to the participant and provide detailed counselling. Participants will not be told

02/03/2020 V5

13

1
2
3 whether they are receiving NRT or placebo lozenges. During hospital stay, the nurse in-charge
4 of the ward will be responsible for daily administration of the medicines to the participant
5 according to standard hospital practice. Participants will be asked to notify a nurse when they
6 wish to have a lozenge (NRT or placebo).
7
8
9
10
11
12
13

14 **Study arms and medicines**

15
16 NRT and placebo (mint) lozenges will be repackaged and labelled in sachets containing two
17 2mg lozenges. For the initial supply, participants will be provided with 12 weeks supply of
18 varenicline and 100 sachets of the NRT/placebo lozenges. The number of lozenges used on
19 average per day will be assessed at the 3-week follow-up. Participants who would like
20 additional supplies of the lozenges can have them delivered to their home by post.
21
22
23
24
25
26
27
28
29

30
31 Participants will be advised to commence the trial medication(s) during their hospital stay. The
32 smoke-free policies of Australian hospitals create an environment conducive for abstinence.
33 Therefore, all participants will be asked to reduce their smoking over the first seven days of
34 varenicline treatment and aim to quit completely within two weeks. Patients will be asked to
35 stop smoking in line with the varenicline Product Information Sheet (35). The RA involved in
36 recruitment will provide verbal counselling to the participants on the dosing regimen, common
37 adverse effects of the study medicines, who to contact in the event of an emergency, their
38 contact details and how to obtain renewed supplies of trial medications. Participants will also
39 be given Consumer Medicines Information (CMI) sheets on the study medicines and a lozenge
40 instruction sheet highlighting key information on the dosing regimen and common adverse
41 effects.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

02/03/2020 V5

14

1
2
3 All study medicines (varenicline and the lozenges) will be initially given for a duration of 12
4 weeks. An additional 12 weeks course of the study medicines (varenicline and the lozenges)
5
6 will be provided to participants who have ceased smoking during the initial course of treatment
7
8 and are undergoing concurrent counselling (e.g. Quitline) for smoking cessation. At week 11
9
10 of treatment, RAs will contact participants in both treatment arms via telephone. At this time-
11
12 point, participants who self-report continuous abstinence (i.e. smoking no more than 5
13
14 cigarettes between week-2 and week-11 of treatment) will be offered an additional 12 weeks
15
16 of treatment using the same study medications. Participants will also be asked about their use
17
18 of the Quitline service since the start of the study. The decision to provide the additional course
19
20 of treatment will be at the discretion of a clinician at the recruiting site based on the
21
22 participant's nicotine dependence, adherence to treatment, any adverse effects they may have
23
24 experienced during the initial course and their severity. Additional supplies of the trial
25
26 medications will be delivered to the participant's home by post or pick-up will be arranged
27
28 from the recruiting hospital.
29
30
31
32
33
34
35
36
37

38 Control arm

39
40 Participants randomised to the control group will receive varenicline plus placebo (mint)
41
42 lozenges. Varenicline will be used at the standard dose as follows: 0.5mg once daily on days
43
44 1-3, 0.5mg twice daily on days 4-7 and 1mg twice daily from day 8 onwards for 11 weeks.
45
46
47
48

49 Intervention arm

50
51 Participants randomised to the intervention arm will receive varenicline plus NRT lozenges.
52
53 Varenicline will be used at the standard dose as in the control arm.
54
55
56
57

58 *NRT/Placebo lozenge dosing schedule (36)*
59
60

02/03/2020 V5

15

1
2
3 Lozenges will be used by participants only when there is an urge to smoke. Participants will
4 be advised to use a lozenge (2mg) as required when they have an urge to smoke (up to every
5 1-2 hours initially) and not to use more than 15 lozenges in a day. Participants will also be
6 advised on how to use the lozenges as per the points below:
7
8
9
10

- 11 1. Place one lozenge on the tongue and suck until the taste becomes strong
 - 12 2. Park the lozenge between the gum and cheek
 - 13 3. When the taste fades start sucking the lozenge again
 - 14 4. Repeat this process until the lozenge completely dissolves (it takes about 30 minutes)
- 15
16
17
18
19
20
21
22
23

24 **Quitline support and text messages**

25 All participants (both intervention and control) will be encouraged to use behavioural support
26 from Quitline as per Quitline standard protocols. However, using Quitline support is not a
27 compulsory requirement for participation in the study.
28
29
30
31
32
33

34 A Quitline referral form will be completed on behalf of the participant by the RA and sent to
35 Quitline following the baseline interview. Quitline staff will contact the participant in the first
36 instance at a suitable time noted on the referral form. Quitline staff will make a total of four
37 attempts to contact the participant. If a participant is unreachable, Quitline will notify the RA
38 at the respective site. The RA will follow this up with the participant at the next scheduled
39 follow-up (1 or 3 weeks).
40
41
42
43
44
45
46
47
48
49
50

51 Automated text messages will be sent to all participants by Quitline using their standard
52 procedures i.e. once a week for the first month of treatment, then once every month. Text
53 messages will reinforce the importance of adherence to the study medicines to increase
54 abstinence and also contain emergency contact details for the participants. Participants who do
55
56
57
58
59
60

02/03/2020 V5

16

1
2
3 not have a mobile phone will be called (with their permission) on their home phone by the RA
4
5 instead of sending text messages.
6
7
8
9

10 **Concomitant treatment**

11
12 Participants will be able to take any other medicines as required, except for smoking cessation
13
14 medicines, after discussing with the prescriber of their involvement in the trial. Use of
15
16 concomitant medicines will be assessed and recorded at each follow-up and verification of any
17
18 potential interactions with the study medicines will be carried out. The use of other smoking
19
20 cessation medicines including other forms of NRT (e.g. patches) will be strongly discouraged
21
22 during the course of the study. If a participant uses other smoking cessation medicines during
23
24 the study period, an appropriate record of this will be maintained. Data from such participants
25
26 will still be included in the primary and secondary analyses, however sensitivity analysis will
27
28 be performed after excluding them from the primary analysis.
29
30
31
32
33
34

35 **Data Collection and follow-up**

36
37 Baseline data will be collected at the time of recruitment. All participants will be followed up
38
39 for a period of 12 months after treatment initiation. Five follow-up interviews will be
40
41 conducted: at weeks one and three of treatment and at three, six and twelve months after the
42
43 start of treatment. The first and second follow-ups will be done by the RA and will be conducted
44
45 face-to-face for participants who are still inpatients, or via telephone for participants who have
46
47 been discharged. Three-, six- and twelve- month follow-ups will be conducted via telephone
48
49 by a RA, who is blinded to treatment allocation and who was not involved in participant
50
51 recruitment. Participants unable to be contacted for follow-ups will be considered as “smokers”
52
53 according to the Russell Standard (37).
54
55
56
57
58
59
60

02/03/2020 V5

17

1
2
3 General demographics including age, gender, ethnicity, highest level of education, employment
4 status and possession of any concession card will be collected at baseline. Medical and
5
6 medical history will be obtained from the patients' hospital notes. Smoking-related
7
8 information such as current smoking status, age at smoking onset, environmental triggers to
9
10 smoking and previous attempts at smoking cessation will also be gathered. In addition to this,
11
12 the study will employ the following validated scales:
13
14

- 15
16
17 ● **Heaviness of Smoking Index (HSI):** the two item scale measures nicotine dependence
18 and considers time to the first cigarette of the day and the number of cigarettes smoked
19 per day (38).
- 20
21
22 ● **Patient Health Questionnaire (PHQ-9):** this nine-item scale will be used to measure
23 and monitor symptoms of depression amongst participants. Each item will be scored on
24 a four point scale ranging from 'not at all' to 'nearly every day'(39).
- 25
26
27 ● **Visual analogue scales** to assess the participants' level of motivation and confidence
28 to quit smoking: a 10-point numerical scale with one being 'very low' to 10 being 'very
29 high' will be used for participants to self-report their motivation and confidence to quit
30 smoking.
- 31
32
33 ● **Mood and physical symptoms scale (MPSS):** This questionnaire assesses the severity
34 of withdrawal symptoms and the strengths and frequencies of patients' urges to smoke.
35 The MPSS involves 5-point ratings of depressed mood, irritability, restlessness,
36 difficulty concentrating and hunger and 6-point ratings of strength of urges to smoke
37 and time spent with urges (40).
- 38
39
40 ● **Tool for adherence behaviour screening (TABS):** This is an 8-item tool that assesses
41 both intentional and unintentional non-adherence, participants rate each adherence
42 behaviour statement on a 5-point scale ranging from 'always' to 'never' (41).
- 43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

18

Blinding

Three-, six- and twelve- month follow-ups will be conducted by a RA blinded to treatment allocation. All possible measures will be taken to prevent participant disclosure of treatment allocation to the RA. Any accidental unblinding will be documented and reported.

Primary endpoints

The primary endpoint is biochemically verified continuous abstinence from 2 weeks to 6 months after treatment initiation. A 2-week period will be allowed on treatment commencement to match the recommended grace period in the varenicline Product Information Sheet (35). Participants who self-report continuous abstinence (i.e. self-report of having smoked no more than five cigarettes, including the use of non-combustible tobacco products and electronic cigarettes) over this period (i.e. weeks 2- 26) will be asked to perform a carbon monoxide (CO) breath test. CO levels will be measured by a trained RA blinded to treatment allocation, using a handheld piCO+ Smokerlyzer (Bedfont Scientific, Maidstone, Kent, UK) during a hospital or home visit. Participants with a CO level <10 ppm will be considered abstinent (18, 42). Sensitivity analysis will be performed using a lower CO cut-off of <5ppm (43).

Secondary endpoints

The secondary outcomes are:

- 1) Participant self-reported continuous abstinence from 2 weeks to three, six and twelve months after treatment initiation
- 2) CO verified continuous abstinence from 2 weeks to 12 months after treatment initiation for participants who self-report abstinence at this follow-up
- 2) Self-reports of withdrawal symptoms and cravings

02/03/2020 V5

19

- 3) Self-reports of adherence to varenicline treatment measured using the TABS
- 4) Self-reports of the number of lozenges consumed per day (NRT or placebo)
- 5) Change in psychological distress
- 6) Adverse events experienced from the study medicines
- 7) Number of Quitline sessions attended/received (self-reported and data transfer from Quitline)
- 8) Self-reported utilisation of other smoking cessation therapies and alternative products (e.g. electronic cigarettes)
- 9) Self-reported 7-day point prevalence abstinence (i.e. smoking not even a puff in the past 7 days on the day of follow-up) at 3, 6 and 12 months after treatment initiation
- 10) CO verified 7-day point prevalence abstinence at 6 and 12 months after treatment initiation for participants who self-report abstinence at these follow-ups

Withdrawal criteria

All participants are strongly encouraged to complete the study, however there may be situations where withdrawal from the study may be appropriate. Participants may withdraw from the study if one or more of the following occur:

- The participant experiences any serious adverse event (SAE) from the use of the study medicines. Prior to treatment discontinuation, input from the treating medical team and Data Safety and Monitoring Board (DSMB) will be sought in establishing the association between treatment exposure and adverse events. The DSMB will review all such cases and make the final judgement on causality.
- If a female participant becomes pregnant during the course of treatment
- If a participant's health status changes significantly and the study medications are no longer in the best interest of the participant

02/03/2020 V5

20

- The lead investigators or health professionals perceive, for any reason, that the study is no longer in the best interest of the participant
- A participant may be withdrawn from the study if he/she wants to do so. Participants are free to withdraw from the study at any time without providing any reason or being disadvantaged.

A participant wishing to withdraw from the study will be asked to complete a 'withdrawal form' for record purposes, but it is not mandatory. Once withdrawn from the study, the participant will not be contacted for further data collection, however the available data will be included in the intention-to-treat analysis. If withdrawal is the result of an adverse drug reaction, the participants will be followed until the adverse reaction resolves or when they return to clinically acceptable medical status.

Sample size

To show an absolute difference of 15% in continuous abstinence rate between study arms (estimate based on continuous abstinence rates in varenicline-NRT trials)(21) at the 5% level of significance with 80% power, we will need 160 subjects per arm. A total of 320 participants will be recruited from the five hospitals, i.e. 64 subjects from each hospital, 32 each in varenicline monotherapy and varenicline + NRT arms. The primary analysis will be by ITT and participants lost to follow-up will be regarded as smokers (37).

Data analysis

The distribution of data will be assessed and analysed using appropriate statistical tests. The baseline demographic and clinical characteristics will be summarised using counts and proportions, mean and standard deviation or median and interquartile range, according to data type and distribution.

02/03/2020 V5

21

1
2
3
4
5
6 As recommended by the Russell Standard, all randomised patients will be accounted for in the
7
8 ITT analysis (37). Participants with missing outcomes at follow-up, or whose self-reported
9
10 abstinence was not biochemically validated will be considered as smokers. Sensitivity analyses
11
12 using multiple imputation methods will also be carried out. Deceased participants will be
13
14 excluded from analyses. In a supportive analysis of the primary efficacy endpoint, an analysis
15
16 will also be conducted on the per protocol set, which excludes patients with any major protocol
17
18 deviations. Use of NRT after admission to the hospital will be captured and adjusted for in the
19
20 analysis. The statistical analysis plan will be finalised to provide a detailed description of all
21
22 the analyses prior to locking of the database.
23
24
25
26
27

28 Continuous abstinence at six and twelve months in each treatment arm will be estimated.
29
30 Differences between arms and the corresponding 95% confidence interval will be determined.
31
32 Primary analysis will be performed using a cut-off CO of <10ppm and additional sensitivity
33
34 analysis will be conducted using a lower cut-off of <5ppm (43). Logistic regression models
35
36 will be used to examine the efficacy of intervention on the primary outcome, after testing
37
38 homogeneity between hospitals using a random effects meta-analysis. In the event of
39
40 heterogeneity, generalised estimating equation models incorporating clustering by hospital
41
42 will be fitted. The effect of intervention on continuous abstinence at 6 and at 12 months will
43
44 be tested in pre-specified subgroups (per hospital, nicotine dependence, highly motivated
45
46 versus moderately motivated smokers and men versus women) using models fitted for each
47
48 subgroup containing main effects for intervention and subgroup and an interaction between
49
50 them. Statistical significance will be set at a two-sided p value of 0.05.
51
52
53
54
55
56
57
58
59
60

02/03/2020 V5

22

All randomised participants who take at least one dose of the treatment medications will be included in the safety analysis. A chi-squared test or Fisher's exact test as appropriate will be used to compare the frequency of treatment withdrawal between the intervention and control groups. The number of participants discontinuing treatment prematurely for any reason will be summarised by treatment group and by reasons for discontinuation.

The incidence of all suspected adverse events will be summarised by treatment group under the following categories: type, severity, action taken and outcome. Adverse event reports detailing the relationship of all adverse events occurs in response to the study medication will also be prepared. Severity of adverse events will be reported using the Common Terminology Criteria for Adverse Events (CTCAE) grading scale (v5.0). The causality of the adverse events will be determined using the Naranjo algorithm (44).

Data safety and monitoring board (DSMB)

To ensure the safety of the study participants and protect the scientific integrity of the trial, a three-member independent DSMB together with a study statistician has been established. The DSMB will periodically review trial safety and outcome data and make recommendations regarding the continuation of the trial based on this information. All serious adverse events (SAEs) will be adjudicated by an end point evaluation committee, which reviews documentation related to the SAE and decides regarding its potential causal relationship with the study drug. Suspected SAEs are also reported as required to the ethics committee of the hospital which enrolled the participant, the human research ethics committee of Monash University, and to the study sponsor. Treatment will be discontinued if there are SAEs or safety concerns relating to the use of the study medicines. Any support necessary to those affected or concerned will be provided independent of the study.

02/03/2020 V5

ETHICS AND DISSEMINATION

The trial will be conducted in compliance with the protocol, the principles of Good Clinical Practice (GCP), the National Health and Medical Research Council (NHMRC) National Statement on Ethical Conduct in Human Research (updated 2015) and the Australian Code for the Responsible Conduct of Research (2018). Approval has been obtained from the Human Ethics Committees of all the participating hospitals and the University. Written informed consent will be obtained from each participant at the time of recruitment.

Both varenicline and NRT have well established safety and efficacy when used appropriately. However, participant safety may still be a concern, especially in combination. Any potential concerns regarding eligibility will be discussed with the treating medical team. Participants in both arms will be closely monitored for any adverse effects.

Participants will receive their CO breath test result immediately after testing. After data analysis, a summary of findings will be sent to participants who requested this information. The research team will submit study findings to peer-reviewed journals. Any protocol changes will be updated on the ANZ Clinical Trials Registry.

PATIENT AND PUBLIC INVOLVEMENT

This research will be done without patient or public involvement. Patients and the public will not be invited to comment on the study design and will not be consulted to develop patient relevant outcomes, interpret the results or contribute to the writing or editing of study documents for readability or accuracy.

DISCUSSION

Abstinance rates are suboptimal despite the wide availability of various smoking cessation therapies (4). A significant number of quit attempts result in failure; despite this no new smoking cessation medication has been approved by the Food and Drugs Administration since varenicline in 2006 (11). Effective combinations of existing smoking cessation therapies are thus needed to further boost abstinence rates.

This is the first multi-centre, placebo-controlled, randomised controlled trial to evaluate the efficacy and safety of a combination of varenicline with acute release forms of NRT. This is also the first pragmatic trial to explore the effectiveness of this combination treatment in achieving long-term abstinence rates among inpatients in Australian hospitals. Varenicline has proven to be one of the most effective smoking cessation therapies, however current literature suggests that it may not completely attenuate nicotine cravings. This effect could be overcome by the addition of an acute release form of NRT (11, 20). If effective this combination treatment may help to further boost abstinence rates and the results of this trial could help guide future smoking cessation treatments and guidelines. Smoking is banned in the premises of all the participating hospitals. This smoke-free environment will help to promote smoking cessation in both the intervention and the control arms of the study.

Some strengths of the current study include the randomisation of participants to the intervention and control arms reducing selection bias and outcome assessment by staff blinded to treatment allocation. The multi-centre design of the trial will ensure that the study sample is representative of the inpatient smokers who are admitted to Australian public hospitals. It will also enable greater generalisability of the study findings. Furthermore, biochemical verification of abstinence used in this trial will enable us to make accurate inferences regarding the

25

effectiveness of the intervention. According to standard practices, public hospitals in Australia offer NRT to inpatient smokers on admission to help them to abide to the hospital's smoke-free policy. As a result, some participants may already be using NRT (e.g. patch) when they are recruited. This may affect the participant's initial response to the study medication and would be one of the potential limitations of this study. Use of NRT after admission to the hospital will be captured and adjusted for in analysis.

TRIAL STATUS

This trial is registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12618001792213). Approval will be sought from the Human Research Ethics Committees of all the participating hospitals and Monash University.

AUTHORS' CONTRIBUTIONS

JG conceived the research idea and developed it with input from other chief investigators, MA, BB, GW, MD, BS, AW and SK and secured research funding. RG is a PhD scholar working on this project under the supervision of JG, MA and BB. All the investigators contributed to all phases of the study including study design, protocol development and finalisation of manuscript. All authors have reviewed this manuscript and have approved the final protocol.

FUNDING

This study is supported by the Global Research Awards for Nicotine Dependence 2017, an independently-reviewed competitive grants program supported by Pfizer.

COMPETING INTERESTS

02/03/2020 V5

1
2
3 Michael Abramson, Billie Bonevski and Johnson George have held investigator-initiated
4 grants from Boehringer Ingelheim (BI) Pty Ltd for an unrelated project. Michael Abramson
5 has also received assistance with conference attendance and conducted an unrelated
6 consultancy for Sanofi. He has also received a speaker's fee from GSK. Johnson George has
7 received honorarium from GSK and Pfizer for consultancy and educational grants for unrelated
8 projects.
9

16 REFERENCES

- 17
18
19 1. Weiland T, Jelinek GA, Taylor SE, Taylor DM. Tobacco smoking by adult emergency
20 department patients in Australia: a point-prevalence study. *Public Health Res Pract.*
21 2016;26(3).
22
23
- 24
25
26 2. Drope Jeffrey SN, Zachary Cahn, Drope Jacqui, Hamill Stephen, Islami Farhad, Liber
27 Alex, Nigar Nargis, Stoklosa Michal. *The Tobacco Atlas*. Atlanta, Georgia 30303 USA:
28 American Cancer Society, Inc.; 2018 2018.
29
30
- 31
32
33 3. Greenhalgh EM, Bayly M, Winstanley MH. 1.3 Prevalence of smoking—adults
34 Melbourne: Cancer Council Victoria; 2019 [updated February 2019. Available from:
35 <https://www.tobaccoinaustralia.org.au/1-3-prevalence-of-smoking-adults#x2>.
36
37
- 38
39
40 4. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking
41 cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev.* 2013(5).
42
43
- 44
45
46 5. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine
47 receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev.* 2016(5).
48
- 49
50
51 6. Jimenez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking
52 cessation. *Drugs.* 2009;69(10):1319-38.
53
- 54
55
56 7. Wadgave U, Nagesh L. Nicotine Replacement Therapy: An Overview. *Int J Health Sci*
57 (Qassim). 2016;10(3):425-35.
58
59
60

27

- 1
2
3 8. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and
4 therapeutics. *Annu Rev Pharmacol Toxicol*. 2009;49:57-71.
- 5
6
7 9. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement
8 therapy versus control for smoking cessation. *Cochrane Database Syst Rev*. 2018(5).
- 9
10
11 10. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking
12 cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev*. 2013(5).
- 13
14
15 11. Berg KM, Jorenby DE, Baker TB, Fiore MC. Triple Smoking Cessation Therapy with
16 Varenicline, Nicotine Patch and Nicotine Lozenge: A Pilot Study to Assess Tolerability,
17 Satisfaction and End-of-Treatment Quit Rates. *J Smok Cessat*. 2017;13(3):145-53.
- 18
19
20 12. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A
21 randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit
22 dates. *Nicotine Tob Res*. 2012;14(3):343-50.
- 23
24
25 13. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for
26 Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. *Circulation*.
27 2016;133(1):21-30.
- 28
29
30 14. Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, et al. Effects
31 of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-
32 controlled study. *Clin Ther*. 2011;33(4):465-77.
- 33
34
35 15. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine
36 receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev*.
37 2016(5):CD006103.
- 38
39
40 16. Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking:
41 what advantages does it offer? *Drugs*. 2010;70(6):643-50.
- 42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

02/03/2020 V5

28

17. Cinciripini PM, Minnix JA, Green CE, Robinson JD, Engelmann JM, Versace F, et al. An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. *Addiction*. 2018.
18. Thomas D, Farrell M, McRobbie H, Tutka P, Petrie D, West R, et al. The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial. *Addiction*. 2019;114(5):923-33.
19. Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer? *Drugs*. 2010;70(6):643-50.
20. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. *BMC Med*. 2014;12:172.
21. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. *Jama*. 2014;312(2):155-61.
22. Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. *BMC Public Health*. 2015;15:689.
23. Ray LA, Lunny K, Bujarski S, Moallem N, Krull JL, Miotto K. The effects of varenicline on stress-induced and cue-induced craving for cigarettes. *Drug Alcohol Depend*. 2013;131(1-2):136-42.
24. Grace C. 15.7 Legislation to ban smoking in public spaces. Melbourne: Cancer Council Victoria; 2016 [updated October 2016. Available from: <http://www.tobaccoaustralia.org.au/chapter-15-smokefree-environment/15-7-legislation>.

02/03/2020 V5

29

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
25. Rigotti NA, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. *Cochrane Database Syst Rev*. 2007(3):CD001837.
26. Pelletier JH, Strout TD, Baumann MR. A systematic review of smoking cessation interventions in the emergency setting. *Am J Emerg Med*. 2014;32(7):713-24.
27. Murray RL, Leonardi-Bee J, Marsh J, Jayes L, Li J, Parrott S, et al. Systematic identification and treatment of smokers by hospital based cessation practitioners in a secondary care setting: cluster randomised controlled trial. *BMJ*. 2013;347:f4004.
28. Rigotti NA, Munafo MR, Stead LF. Smoking Cessation Interventions for Hospitalized Smokers: A Systematic Review. *Arch Intern Med*. 2008;168(18):1950-60.
29. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. *Chest*. 2007;131(2):446-52.
30. Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalised patients. *Cochrane Database Syst Rev*. 2012;5(5):Cd001837.
31. Mendelsohn C. Managing nicotine dependence in NSW hospitals under the Smoke-free Health Care Policy. *Public Health Res Pract*. 2015;25(3):e2531533.
32. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *Jama*. 2006;296(1):47-55.
33. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *Jama*. 2006;296(1):56-63.

02/03/2020 V5

30

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
34. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *Jama*. 2006;296(1):64-71.
35. Pfizer Australia Pty Ltd. Product information. Champix (as varenicline tartrate). .
36. Novartis Consumer Health GmbH. Package leaflet: information for the user. Nicotinell mint 1mg compressed lozenge.
37. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction*. 2005;100(3):299-303.
38. Borland R, Yong HH, O'Connor RJ, Hyland A, Thompson ME. The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study. *Nicotine Tob Res*. 2010;12 Suppl:S45-50.
39. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606-13.
40. West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. *Psychopharmacology (Berl)*. 2004;177(1-2):195-9.
41. George J, Mackinnon A, Kong DC, Stewart K. Development and validation of the Beliefs and Behaviour Questionnaire (BBQ). *Patient Educ Couns*. 2006;64(1-3):50-60.
42. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. *Nicotine Tob Res*. 2002;4(2):149-59.
43. Perkins KA, Karelitz JL, Jao NC. Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence. *Nicotine Tob Res*. 2013;15(5):978-82.
44. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther*. 1981;30(2):239-45.

02/03/2020 V5

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

	Reporting Item	Page Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered,	2 & 25
2			name of intended registry	
3				
4				
5				
6	Trial registration: data	#2b	All items from the World Health Organization Trial	n/a
7	set		Registration Data Set	
8				
9				
10				
11	Protocol version	#3	Date and version identifier	1
12				
13				
14				
15	Funding	#4	Sources and types of financial, material, and other support	25
16				
17				
18	Roles and	#5a	Names, affiliations, and roles of protocol contributors	25
19	responsibilities:			
20	contributorship			
21				
22				
23				
24				
25				
26	Roles and	#5b	Name and contact information for the trial sponsor	25
27	responsibilities:			
28	sponsor contact			
29	information			
30				
31				
32				
33				
34				
35				
36	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	n/a
37	responsibilities:		collection, management, analysis, and interpretation of	
38	sponsor and funder		data; writing of the report; and the decision to submit the	
39			report for publication, including whether they will have	
40			ultimate authority over any of these activities	
41				
42				
43				
44				
45				
46				
47				
48	Roles and	#5d	Composition, roles, and responsibilities of the coordinating	22
49	responsibilities:		centre, steering committee, endpoint adjudication	
50	committees		committee, data management team, and other individuals	
51			or groups overseeing the trial, if applicable (see Item 21a	
52			for data monitoring committee)	
53				
54				
55				
56				
57				
58				
59				
60				

1	Introduction			
2				
3				
4	Background and	#6a	Description of research question and justification for	5
5				
6	rationale		undertaking the trial, including summary of relevant studies	
7			(published and unpublished) examining benefits and harms	
8			for each intervention	
9				
10				
11				
12				
13				
14	Background and	#6b	Explanation for choice of comparators	7
15				
16	rationale: choice of			
17				
18	comparators			
19				
20				
21				
22	Objectives	#7	Specific objectives or hypotheses	9
23				
24				
25	Trial design	#8	Description of trial design including type of trial (eg, parallel	9
26			group, crossover, factorial, single group), allocation ratio,	
27			and framework (eg, superiority, equivalence, non-inferiority,	
28			exploratory)	
29				
30				
31				
32				
33				
34				
35	Methods:			
36				
37	Participants,			
38				
39	interventions, and			
40				
41	outcomes			
42				
43				
44				
45	Study setting	#9	Description of study settings (eg, community clinic,	9
46			academic hospital) and list of countries where data will be	
47			collected. Reference to where list of study sites can be	
48			obtained	
49				
50				
51				
52				
53				
54	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	10
55			applicable, eligibility criteria for study centres and	
56				
57				
58				
59				
60				

1		individuals who will perform the interventions (eg,	
2		surgeons, psychotherapists)	
3			
4			
5			
6	Interventions:	#11a Interventions for each group with sufficient detail to allow	13
7			
8	description	replication, including how and when they will be	
9			
10		administered	
11			
12			
13	Interventions:	#11b Criteria for discontinuing or modifying allocated	19
14			
15	modifications	interventions for a given trial participant (eg, drug dose	
16		change in response to harms, participant request, or	
17			
18		improving / worsening disease)	
19			
20			
21			
22			
23	Interventions:	#11c Strategies to improve adherence to intervention protocols,	17
24			
25	adherence	and any procedures for monitoring adherence (eg, drug	
26			
27		tablet return; laboratory tests)	
28			
29			
30			
31	Interventions:	#11d Relevant concomitant care and interventions that are	16
32			
33	concomitant care	permitted or prohibited during the trial	
34			
35			
36	Outcomes	#12 Primary, secondary, and other outcomes, including the	18
37			
38		specific measurement variable (eg, systolic blood	
39		pressure), analysis metric (eg, change from baseline, final	
40			
41		value, time to event), method of aggregation (eg, median,	
42			
43		proportion), and time point for each outcome. Explanation	
44			
45		of the clinical relevance of chosen efficacy and harm	
46			
47		outcomes is strongly recommended	
48			
49			
50			
51			
52			
53	Participant timeline	#13 Time schedule of enrolment, interventions (including any	
54			
55		run-ins and washouts), assessments, and visits for	
56			
57		participants. A schematic diagram is highly recommended	
58			
59			
60			

1		(see Figure)	
2			
3			
4	Sample size	#14 Estimated number of participants needed to achieve study	20
5			
6		objectives and how it was determined, including clinical and	
7			
8		statistical assumptions supporting any sample size	
9			
10		calculations	
11			
12			
13	Recruitment	#15 Strategies for achieving adequate participant enrolment to	11
14			
15		reach target sample size	
16			
17			
18			
19	Methods: Assignment		
20			
21	of interventions (for		
22			
23	controlled trials)		
24			
25			
26	Allocation: sequence	#16a Method of generating the allocation sequence (eg,	12
27			
28	generation	computer-generated random numbers), and list of any	
29			
30		factors for stratification. To reduce predictability of a	
31			
32		random sequence, details of any planned restriction (eg,	
33			
34		blocking) should be provided in a separate document that is	
35			
36		unavailable to those who enrol participants or assign	
37			
38		interventions	
39			
40			
41			
42			
43	Allocation	#16b Mechanism of implementing the allocation sequence (eg,	12
44			
45	concealment	central telephone; sequentially numbered, opaque, sealed	
46			
47	mechanism	envelopes), describing any steps to conceal the sequence	
48			
49		until interventions are assigned	
50			
51			
52			
53	Allocation:	#16c Who will generate the allocation sequence, who will enrol	11&12
54			
55	implementation	participants, and who will assign participants to	
56			
57		interventions	
58			
59			
60			

1	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg,	18
2			trial participants, care providers, outcome assessors, data	
3			analysts), and how	
4				
5				
6				
7				
8	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is	18
9	emergency		permissible, and procedure for revealing a participant's	
10			allocated intervention during the trial	
11	unblinding			
12				
13				
14				
15				
16	Methods: Data			
17	collection,			
18	management, and			
19	analysis			
20				
21				
22				
23				
24				
25				
26	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline,	16
27			and other trial data, including any related processes to	
28			promote data quality (eg, duplicate measurements, training	
29			of assessors) and a description of study instruments (eg,	
30			questionnaires, laboratory tests) along with their reliability	
31			and validity, if known. Reference to where data collection	
32			forms can be found, if not in the protocol	
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43	Data collection plan:	#18b	Plans to promote participant retention and complete follow-	n/a
44	retention		up, including list of any outcome data to be collected for	
45			participants who discontinue or deviate from intervention	
46			protocols	
47				
48				
49				
50				
51				
52				
53	Data management	#19	Plans for data entry, coding, security, and storage,	
54			including any related processes to promote data quality	
55			(eg, double data entry; range checks for data values).	
56				
57				
58				
59				
60				

1		Reference to where details of data management	
2			
3		procedures can be found, if not in the protocol	
4			
5			
6	Statistics: outcomes	#20a Statistical methods for analysing primary and secondary	20
7			
8		outcomes. Reference to where other details of the	
9			
10		statistical analysis plan can be found, if not in the protocol	
11			
12			
13	Statistics: additional	#20b Methods for any additional analyses (eg, subgroup and	20-22
14			
15	analyses	adjusted analyses)	
16			
17			
18			
19	Statistics: analysis	#20c Definition of analysis population relating to protocol non-	21
20			
21	population and	adherence (eg, as randomised analysis), and any statistical	
22			
23	missing data	methods to handle missing data (eg, multiple imputation)	
24			
25			
26	Methods: Monitoring		
27			
28			
29	Data monitoring:	#21a Composition of data monitoring committee (DMC);	
30			
31	formal committee	summary of its role and reporting structure; statement of	
32			
33		whether it is independent from the sponsor and competing	
34			
35		interests; and reference to where further details about its	
36			
37		charter can be found, if not in the protocol. Alternatively, an	
38			
39		explanation of why a DMC is not needed	
40			
41			
42			
43			
44	Data monitoring:	#21b Description of any interim analyses and stopping	23
45			
46	interim analysis	guidelines, including who will have access to these interim	
47			
48		results and make the final decision to terminate the trial	
49			
50			
51	Harms	#22 Plans for collecting, assessing, reporting, and managing	22
52			
53		solicited and spontaneously reported adverse events and	
54			
55		other unintended effects of trial interventions or trial	
56			
57			
58			
59			
60			

1		conduct	
2			
3			
4	Auditing	#23 Frequency and procedures for auditing trial conduct, if any,	
5		and whether the process will be independent from	
6			
7			
8		investigators and the sponsor	
9			
10			
11	Ethics and		
12			
13	dissemination		
14			
15			
16	Research ethics	#24 Plans for seeking research ethics committee / institutional	23
17			
18	approval	review board (REC / IRB) approval	
19			
20			
21	Protocol	#25 Plans for communicating important protocol modifications	23
22			
23	amendments	(eg, changes to eligibility criteria, outcomes, analyses) to	
24		relevant parties (eg, investigators, REC / IRBs, trial	
25		participants, trial registries, journals, regulators)	
26			
27			
28			
29			
30			
31	Consent or assent	#26a Who will obtain informed consent or assent from potential	11
32		trial participants or authorised surrogates, and how (see	
33		Item 32)	
34			
35			
36			
37			
38			
39	Consent or assent:	#26b Additional consent provisions for collection and use of	n/a
40			
41	ancillary studies	participant data and biological specimens in ancillary	
42		studies, if applicable	
43			
44			
45			
46			
47	Confidentiality	#27 How personal information about potential and enrolled	23
48			
49		participants will be collected, shared, and maintained in	
50		order to protect confidentiality before, during, and after the	
51			
52		trial	
53			
54			
55			
56			
57	Declaration of	#28 Financial and other competing interests for principal	25
58			
59			
60			

1	interests		investigators for the overall trial and each study site	
2				
3				
4	Data access	#29	Statement of who will have access to the final trial dataset,	
5			and disclosure of contractual agreements that limit such	
6			access for investigators	
7				
8				
9				
10				
11	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care, and for	22
12			compensation to those who suffer harm from trial	
13	trial care		participation	
14				
15				
16				
17				
18				
19	Dissemination policy:	#31a	Plans for investigators and sponsor to communicate trial	23
20			results to participants, healthcare professionals, the public,	
21	trial results		and other relevant groups (eg, via publication, reporting in	
22			results databases, or other data sharing arrangements),	
23			including any publication restrictions	
24				
25				
26				
27				
28				
29				
30				
31	Dissemination policy:	#31b	Authorship eligibility guidelines and any intended use of	n/a
32			professional writers	
33	authorship			
34				
35				
36	Dissemination policy:	#31c	Plans, if any, for granting public access to the full protocol,	n/a
37			participant-level dataset, and statistical code	
38	reproducible research			
39				
40				
41				
42	Appendices			
43				
44				
45	Informed consent	#32	Model consent form and other related documentation given	
46			to participants and authorised surrogates	
47	materials			
48				
49				
50	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of	
51			biological specimens for genetic or molecular analysis in	
52			the current trial and for future use in ancillary studies, if	
53			applicable	
54				
55				
56				
57				
58				
59				
60				

1 None The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution
2 License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a
3 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

The efficacy and safety of varenicline alone versus in combination with nicotine lozenges for smoking cessation among hospitalised smokers (VANISH): study protocol for a randomised, placebo-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038184.R1
Article Type:	Protocol
Date Submitted by the Author:	11-May-2020
Complete List of Authors:	Gobarani, Rukshar; Monash University - Parkville Campus, Centre for Medicine Use and Safety Abramson, Michael; Monash University, Dept of Epidemiology and Preventive Medicine Bonevski, Billie; University of Newcastle, School of Medicine & Public Health Weeks, Gregory; Barwon Health Dooley, Michael; Monash University, Centre for Medicine Use and Safety; The Alfred, Pharmacy Department Smith, Brian; Bendigo Health - Bendigo Hospital Campus, Department of Clinical Epidemiology and Biostatistics Veale, Antony; The Queen Elizabeth Hospital, Department of Respiratory Medicine Webb, Ashley; Frankston Hospital, Department of Anaesthesia and Pain Management Kirsas, Sue; Monash Health, Pharmacy Thomas, Dennis; The University of Newcastle Hunter Medical Research Institute, Priority Research Centre for Healthy Lungs Miller, Alistair; Royal Melbourne Hospital, Respiratory and Sleep Medicine Gasser, Rudi; Barwon Health, Department of General Medicine Paul, Eldho; Monash University, School of Public Health and Preventive Medicine; Alfred Health, Clinical Haematology Department Parkinson, Jacqueline; Monash Health, Pharmacy Meanger, Darshana; Frankston Hospital, Pharmacy Coward, Lisa; Frankston Hospital, Anaesthesia Kopsaftis, Zoe; The Queen Elizabeth Hospital, Respiratory Medicine and Clinical Practice Unit Rofe, Olivia; Eastern Health Foundation, Pharmacy Lee, Paula; Eastern Health Foundation, Pharmacy George, Johnson; Monash University, Centre for Medicine Use and Safety
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Addiction, Public health, Smoking and tobacco
Keywords:	PUBLIC HEALTH, Clinical trials < THERAPEUTICS, PRIMARY CARE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

2
3 **The efficacy and safety of varenicline alone versus in combination with nicotine**
4 **lozenges for smoking cessation among hospitalised smokers (VANISH): study protocol**
5 **for a randomised, placebo-controlled trial**
6
7
8

9
10 Authors:

11
12 **Miss Rukshar K. Gobarani**, BPharm (Hons), Centre for Medicine Use and Safety, Monash
13 University, Parkville, Victoria, Australia; rukshar.gobarani@monash.edu
14

15
16 **Prof Michael J. Abramson**, PhD, FRACP, School of Public Health and Preventive
17 Medicine, Monash University, Melbourne, Victoria, Australia;
18
19 michael.abramson@monash.edu
20
21

22
23 **Prof Billie Bonevski**, PhD, School and Medicine and Public Health, University of
24 Newcastle, Callaghan, New South Wales, Australia; billie.bonevski@newcastle.edu.au
25
26

27
28 **Dr Gregory R. Weeks**, PhD, Pharmacy Department, Barwon Health, Geelong, Victoria,
29 Australia; greg@barwonhealth.org.au
30
31

32
33 **Prof Michael J. Dooley**, PhD, Centre for Medicine Use and Safety, Monash University,
34 Parkville, Victoria, Australia; Pharmacy Department, The Alfred, Prahran, Victoria,
35 Australia; M.Dooley@alfred.org.au
36
37

38
39 **Prof Brian J. Smith**, MBBS, FRACP, PhD, Dip Clin Epi and Biostats, Bendigo Hospital,
40 Victoria, Australia; bsmith555@bigpond.com
41
42

43
44 **Dr Antony Veale**, MBBS, FRACP, Department of Respiratory Medicine, The Queen
45 Elizabeth Hospital, Adelaide, Australia; antony.veale@sa.gov.au
46
47

48
49 **Dr Ashley Webb**, MBBS (Hons), MPH, FANZCA Department of Anaesthesia and Pain
50 Management, Peninsula Health, Frankston, Victoria, Australia; AWebb@phcn.vic.gov.au
51
52

53
54 **A/Prof Sue Kirsa**, Grad Dip Hosp Pharm, Pharmacy Department, Monash Health, Clayton,
55 Victoria, Australia; Sue.Kirsa@monash.edu
56
57

58
59
60
22/04/2020 V6

2

Dr Dennis Thomas, PhD, Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, University of Newcastle, New South Wales, Australia;

dennis.thomas@newcastle.edu.au

Dr Alistair Miller, MBBS, Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia; alistair.miller3@mh.org.au

Dr Rudi Gasser, MBBS, Department of General Medicine, Barwon Health, Geelong, Victoria, Australia; rudig@barwonhealth.org.au

Dr Eldho Paul, PhD, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Clinical Haematology Department, The Alfred, Melbourne, Victoria, Australia; eldho.paul@monash.edu

Ms Jacqueline Parkinson, MPharm, Pharmacy Department, Monash Health, Clayton, Victoria, Australia; Jacqueline.Parkinson@monashhealth.org

Miss Darshana Meanger, BPharm, Grad Cert Pharm Prac, Pharmacy Department, Peninsula Health, Frankston, Victoria, Australia; DMeanger@phcn.vic.gov.au

Ms Lisa Coward, EEN, Department of Anaesthesia, Peninsula Health, Frankston, Victoria, Australia; LCoward@phcn.vic.gov.au

Dr Zoe Kopsaftis, PhD, BHSc (Hons), Respiratory Medicine and Clinical Practice Unit, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Zoe.Kopsaftis@sa.gov.au

Ms Olivia Rofe, BPharm, MPharm (Clin), Prof Cert Health Syst Management, Pharmacy Department, Eastern Health, Melbourne, Victoria, Australia;

Olivia.Rofe@easternhealth.org.au

Ms Paula Lee, BPharm, Grad Dip Clin Res, Pharmacy Department, Eastern Health, Box Hill, Victoria, Australia; Paula.Lee@easternhealth.org.au

Dr Johnson George (*corresponding author*), PhD, Centre for Medicine Use and Safety, Parkville, Victoria, Australia; johnson.george@monash.edu

22/04/2020 V6

ABSTRACT

Introduction: Smoking is a leading cause of premature deaths globally. The health benefits of smoking cessation are many. However, majority of quit attempts are unsuccessful. One way to potentially improve success rates is to evaluate new combinations of existing smoking cessation therapies that may work synergistically to decrease the intensity of withdrawal symptoms and cravings.

Aims: To evaluate the feasibility, efficacy and safety of the combination of varenicline and nicotine replacement therapy (NRT) lozenges versus varenicline alone in assisting hospitalised smokers to quit.

Methods and analysis: This is a multi-centre, randomised, placebo-controlled trial. Adults with a history of smoking ≥ 10 cigarettes per day on average in the four weeks prior to their hospitalisation will be recruited. Participants will be randomly assigned to either the intervention group and will receive varenicline and NRT lozenges, or the control group and will receive varenicline and placebo lozenges. In addition to this, all participants will be actively referred to behavioural support from telephone Quitline. Participants are followed up at 1 and 3 weeks and 3, 6 and 12 months from the start of treatment. The primary outcome is carbon monoxide (CO) validated continuous abstinence from 2 weeks to 6 months after treatment initiation. Secondary outcomes include self-reported and biochemically validated continuous and point prevalence abstinence at 3, 6 and 12 months, self-reported adverse events, withdrawal symptoms and cravings, adherence to treatment, Quitline sessions attended etc. According to the Russell standard, all randomised participants will be accounted for in the primary intention-to-treat analysis.

Ethics and dissemination: The trial will be conducted in compliance with the protocol, the principles of Good Clinical Practice, the National Health and Medical Research Council

4

(NHMRC) National Statement on Ethical Conduct in Human Research (updated 2015) and the Australian Code for the Responsible Conduct of Research (2018). Approval will be sought from the Human Ethics Committees of all the participating hospitals and the University. Written informed consent will be obtained from each participant at the time of recruitment.

Trial registration: Australia New Zealand Clinical Trials Registry:

ACTRN12618001792213

Strengths and limitations of this study:

- This is the first multi-centre, randomised, placebo-controlled trial to evaluate the efficacy and safety of a combination of varenicline and an immediate-release form of NRT.
- This is also the first pragmatic trial exploring the effectiveness of this combination treatment in achieving long-term abstinence rates among inpatients in Australian hospitals.
- The multi-centre pragmatic design of the trial will ensure that the study sample is representative of the inpatient smokers who are admitted to Australian public hospitals allowing greater generalizability of study findings
- Biochemical verification of abstinence used in this trial will enable us to make accurate inferences regarding the effectiveness of the intervention.

BACKGROUND

Tobacco smoking is one of the leading causes of preventable morbidity and mortality around the world. Representing a key risk factor for deaths due to ischaemic heart disease, stroke and cancer, tobacco smoking kills approximately six million people globally each year (1). Holding the potential to damage nearly every organ system in the human body, tobacco smoking accounts for 7.8% of the total burden of disease in Australia (1, 2). Despite this, 14% of adults aged 18 years and over smoked daily in 2017-2018 (3).

Various therapeutic agents are currently available to assist in quitting smoking. A substantial body of research has demonstrated the effectiveness of such therapies in increasing abstinence rates (4). Of these, varenicline is the most effective single agent for abstinence outcomes. Available as a prescription only medicine in Australia, varenicline at the standard dose more than doubles the chances of quitting compared with placebo (pooled RR for continuous or sustained abstinence at six months or longer 2.24; 95% CI 2.06 to 2.43) (5). It has a dual mechanism of action and exerts its effects by acting as a partial agonist at the $\alpha 4\beta 2$ nicotinic receptors in the brain (6). This reduces the drop in the mesolimbic dopaminergic levels that occurs during smoking cessation, relieving withdrawal symptoms (6). Varenicline also antagonises the activity of nicotine on its receptors which prevents the release of neurotransmitters such as dopamine and in doing so reduces feelings of pleasure experienced from a smoking relapse (6).

Nicotine replacement therapy (NRT) is another first line treatment for those seeking pharmacological help to quitting smoking (4). NRT replaces some of the nicotine in the blood that was previously derived from cigarettes, without the presence of the thousands of other chemicals that are also produced during tobacco combustion which are largely responsible for

6

causing tobacco-related illnesses (7, 8). In this manner, NRT decreases the intensity of withdrawal symptoms and cigarette cravings (7, 8).

In many countries, NRT is available over-the-counter in acute release formulations such as gums, lozenges, inhalers, mouth sprays and sublingual tablets and in slow release forms such as transdermal patches. Transdermal patches release nicotine slowly over a prolonged period of time (24 or 16 hour patches available) whereas, acute release forms of NRT provide a faster release of nicotine in the blood (7). Acute-dosing products allow the user to titrate both the amount and timing of their doses (7). Therefore, these forms of NRT can be used as “rescue-medication” by smokers to alleviate cigarette cravings (7).

NRTs are more effective than placebo in achieving long-term smoking abstinence (RR of abstinence for any form of NRT relative to control 1.55; 95% CI 1.49 to 1.61) (9). Various forms of NRT perform similarly against each other [pooled RRs of 1.64 for nicotine patch (95% CI 1.53 to 1.75); 1.49 for nicotine gum (95% CI 1.40 to 1.60) and 1.52 for oral tablets/lozenges (95% CI 1.32 to 1.74) relative to control], and evidence suggests that the use of two forms of NRT; a slow release formulation with an acute release formulation (i.e. combination NRT) is more effective than using a single form of NRT (9, 10).

Research to date suggests that varenicline (as monotherapy) and combination NRT are the most effective smoking cessation therapies that are currently available to assist in achieving abstinence (4). Even these, however, result in only modest increases in abstinence rates of approximately 30-40% at 6 months compared with placebo (11-15). A substantial amount of research is thus focused on evaluating new treatment options and approaches for smoking cessation to further increase abstinence rates (11).

22/04/2020 V6

7

1
2
3 In attempts to improve smoking cessation rates, new combinations of existing smoking
4 cessation therapies have been evaluated (16-18). Current research suggests that varenicline
5 may not fully saturate the nicotinic acetylcholine receptors in the brain (19). This in turn leads
6 to only a partial attenuation of nicotine cravings (20). It has been postulated that adding NRT
7 to varenicline treatment may therefore increase receptor saturation, which in turn may decrease
8 cigarette cravings more completely (19, 20).
9
10
11
12
13
14
15
16
17
18

19 In response to this, studies have evaluated the effectiveness of the combination of varenicline
20 and NRT patches versus varenicline monotherapy on smoking cessation rates, although
21 findings have been equivocal (20, 21). A systematic review and meta-analysis of three
22 randomised controlled trials demonstrated that the combination of varenicline and NRT patches
23 was associated with significantly higher rates of abstinence versus varenicline alone at the end
24 of treatment i.e. at 12 weeks (OR 1.50; 95% CI 1.14 to 1.97) and at 6 months (OR 1.62; 95%
25 CI 1.18 to 2.23) (22). This association, however, did not exist when the largest of the three
26 trials, which also used a pre-quit nicotine patch, was excluded from the analysis (22).
27
28
29
30
31
32
33
34
35
36
37
38
39

40 No studies to date have evaluated the effectiveness of the combination of varenicline and acute
41 release forms of NRT which have proven to be just as effective as NRT patches in assisting
42 smokers to quit (9). Secondly, steady-state plasma varenicline concentrations are achieved after
43 approximately four days of continued treatment (19). During this time, patients may experience
44 significant discomfort from withdrawal symptoms and often continue to smoke for several
45 weeks after initiating varenicline therapy (19). Furthermore, a study reported that while
46 varenicline reduces both tonic and cue-induced cigarette cravings, it does not attenuate cue-
47 induced cravings after stress induction compared to placebo (23). In such situations, the use of
48 an *ad lib* NRT product in combination with varenicline would thus enable patients to better
49
50
51
52
53
54
55
56
57
58
59
60

22/04/2020 V6

8

1
2
3 manage their withdrawal symptoms and cravings particularly to prevent stress and cue-related
4
5 reinstatement of smoking (19, 23).
6
7
8
9

10 Smoking inside public hospitals and within 4 meters of the entrances to all public hospitals is
11
12 prohibited in Australia (24). This restriction provides a window of opportunity for the
13
14 implementation of smoking cessation interventions as inpatient smokers are placed away from
15
16 their usual environmental triggers of smoking (25). During this time of increased vulnerability
17
18 regarding their health, patients may be more motivated to quit and may also be more receptive
19
20 to smoking cessation interventions and a change in behaviour particularly if they are presenting
21
22 with conditions that may be caused or exacerbated by smoking (26-30).
23
24
25
26
27

28 Furthermore, hospitalised inpatients generally smoke a greater number of cigarettes per day
29
30 than the general population and have a higher level of nicotine dependence (1, 31). Varenicline
31
32 is a smoking cessation agent that is targeted towards moderate to heavy smokers (32-34).
33
34 Therefore, this group of patients provide an ideal study population for evaluating the efficacy
35
36 and safety of the combination of varenicline and nicotine lozenges for smoking cessation. In
37
38 addition to this, an inpatient setting allows the trial medications to be commenced and
39
40 administered under clinical supervision of hospital staff. This would ensure that participants
41
42 have immediate access to a healthcare professional for medication education or management
43
44 of an adverse drug event due to any trial medication. This study, therefore, aims to evaluate the
45
46 effectiveness and safety of the combination of varenicline and NRT lozenges versus varenicline
47
48 monotherapy in assisting hospitalised smokers in quitting.
49
50
51
52
53
54

55 **Objectives**

56
57
58
59
60

22/04/2020 V6

9

The primary objective of the study is to compare biochemically-verified continuous abstinence at 6 months in hospitalised smokers treated using varenicline plus NRT lozenges with those treated with varenicline and placebo lozenges.

The secondary objectives of this study are to compare the differences between treatment groups on the following outcomes:

- CO verified continuous abstinence from 2 weeks to 12 months after treatment initiation for participants who self-report abstinence at the 12-month follow-up
- Self-reported 7-day point prevalence abstinence and continuous abstinence measured from 2 weeks to 3, 6 and 12 months after treatment initiation
- CO verified 7-day point prevalence abstinence from 2 weeks to 6 and 12 months after treatment initiation for participants who self-report abstinence at these follow-ups
- Self-reported treatment adherence and adverse events to the study medicines at all follow-ups as well as number of Quitline sessions attended after treatment initiation.

METHODS

Study design

A randomised, placebo-controlled, multi-centre, double blinded study

Setting and Participants

Participants will be recruited from the inpatient wards of five 'smoke-free' public hospitals in Australia. Participants will be screened for eligibility at baseline and written informed consent will be sought. Eligible participants will be randomised to either the intervention or control group and will be followed up for 12 months from treatment initiation.

22/04/2020 V6

Inclusion and Exclusion criteria

Patients eligible for the trial are: adults ≥ 18 years, admitted to participating hospitals with a history of smoking ≥ 10 cigarettes per day on average in the four weeks prior to their hospital admission, interested in quitting smoking, willing to use pharmacotherapy, available for a 12 months follow-up post-treatment initiation and willing/capable to provide written informed consent.

Patients who do not meet all of the above inclusion criteria, those who have a terminal illness with an anticipated survival of < 6 months, those who have an unstable cardiovascular status (recent myocardial infarction or stroke within the past 3 months) or those with a new diagnosis of a major psychiatric illness (e.g. psychosis) within the past 3 months will be excluded from the study. Patients unable to provide informed written consent because of their admitting medical condition or health status at the time of recruitment (e.g. patients in intensive care unit or patients with an acute psychiatric condition) will be excluded from the trial. Patients unable to communicate in English and provide written consent will also be excluded given the potential need to regularly communicate with the investigators during the entire trial period, and the lack of funding for interpreters.

Further exclusion criteria for this study are: women who are pregnant, breastfeeding or planning to become pregnant in the next 6 months and patients who were already using smoking cessation medications or approaches at the time of their hospital admission (i.e. NRT, varenicline, bupropion, clonidine, nortriptyline, or electronic nicotine delivering systems). In addition to this, patients who are currently participating in other smoking cessation programs/studies, those who have completed ≥ 12 weeks course of varenicline in the 12 months prior to hospitalisation (these patients may have a higher nicotine dependence and may not

11

1
2
3 respond well to sole varenicline therapy), those who have had intolerable/serious adverse
4 events from the use of varenicline or NRTs in the past, and those who have contraindications
5 for their use (including those using medications known to have major interactions with either
6 varenicline or NRT) will be excluded from the study.
7
8
9
10
11
12
13

14 **Participant recruitment**

15
16 Eligible participants will be identified through active screening of hospital records by a trained
17 Research Assistant (RA), a nurse or a pharmacist employed at each site. Ward staff including
18 doctors, nurses, pharmacists and physiotherapists will be informed of the study and asked to
19 refer all patients identified as current smokers to the RA. Flyers containing study information
20 will be displayed in hospital wards to notify inpatients of the study. Flyers will contain the
21 contact information of the RA at the site so that interested patients can discuss the study with
22 them.
23
24
25
26
27
28
29
30
31
32
33
34

35 Once potential participants are identified, the RA in consultation with the treating medical team
36 will assess each patient's eligibility for the study considering their current health status and any
37 apparent contraindications for the use of varenicline or NRT. Details of this initial medical
38 screening will be recorded by the RA. The RA will then approach eligible patients, describe
39 the project to each potential participant, provide a plain language statement and answer any
40 questions. If the patient is interested in participating, written informed consent will be sought
41 before proceeding with the baseline interview.
42
43
44
45
46
47
48
49
50
51
52
53

54 **Baseline data collection**

55
56 Each participant will be assigned a study number and baseline data collected. Data gathered
57 during the interview will include information on the participant's smoking habits, previous
58
59
60

22/04/2020 V6

12

1
2
3 attempts at quitting and current willingness/confidence to quit. A detailed medical history
4 (current medical conditions and medications) including the presence of any contraindications
5 or precautions for the use of the study medicines (based on the Product Information Sheets)
6 will be sought. Participants with any exclusion criterion will not be enrolled, and will be
7 referred to Quitline for smoking cessation support. Participants who do not meet any of the
8 exclusion criteria, but who have a specified precaution for the use of the trial medications, will
9 be referred to an in-house clinician for further assessment. The decision on whether to include
10 such participants will be at the discretion of the treating medical team, the RA and the patient
11 based on an evaluation of the potential risks and benefits from participation in the study.
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 The baseline interview will also involve an assessment of the presence of psychological distress
27 using the Patient Health Questionnaire (PHQ-9). Once baseline data collection is completed,
28 to ensure the safe ongoing delivery of healthcare services to participants, the RA will seek the
29 participants' consent to contact their regular general practitioner (GP) and community
30 pharmacist to inform them of their patient's participation in the study.
31
32
33
34
35
36
37
38
39

40 **Randomisation: allocation concealment and sequence generation**

41
42 Following the collection of baseline data, participants will be randomised to one of the study
43 arms by a clinical trials pharmacist at each of the five hospitals using a computer-generated
44 randomisation list. Randomisation is stratified by site and random permuted block sizes of two
45 and four will be used. Sealed opaque envelopes will be used for the concealment of treatment
46 allocation. Each site will be provided with 64 envelopes containing group allocation. The
47 clinical trials pharmacist at each site will open the envelopes in a sequential manner when a
48 participant is recruited to identify group allocation. Once a participant's group allocation has
49 been noted along with the study ID, study medicines will be charted on the participant's
50
51
52
53
54
55
56
57
58
59
60

22/04/2020 V6

13

1
2
3 medication chart by a clinician involved in the study. The clinical trials pharmacist will then
4 dispense the study medicines as stated in the envelope ([varenicline and NRT lozenges] or
5 [varenicline and placebo lozenges]) and hand these to the RA. The RA will then give the
6 medicines to the participant and provide detailed counselling. Participants will not be told
7 whether they are receiving NRT or placebo lozenges. During hospital stay, the nurse in-charge
8 of the ward will be responsible for daily administration of the medicines to the participant
9 according to standard hospital practice. Participants will be asked to notify a nurse when they
10 wish to have a lozenge (NRT or placebo).
11
12
13
14
15
16
17
18
19
20
21
22
23

24 **Study arms and medicines**

25
26 NRT and placebo (mint) lozenges will be repackaged and labelled in sachets containing two
27 2mg lozenges. For the initial supply, participants will be provided with 12 weeks supply of
28 varenicline and 100 sachets of the NRT/placebo lozenges. The number of lozenges used on
29 average per day will be assessed at the 3-week follow-up. Participants who would like
30 additional supplies of the lozenges can have them delivered to their home by post.
31
32
33
34
35
36
37
38
39

40 Participants will be advised to commence the trial medication(s) during their hospital stay. The
41 smoke-free policies of Australian hospitals create an environment conducive for abstinence.
42 Therefore, all participants will be asked to reduce their smoking over the first seven days of
43 varenicline treatment and aim to quit completely within two weeks. Patients will be asked to
44 stop smoking in line with the varenicline Product Information Sheet (35). The RA involved in
45 recruitment will provide verbal counselling to the participants on the dosing regimen, common
46 adverse effects of the study medicines, who to contact in the event of an emergency, their
47 contact details and how to obtain renewed supplies of trial medications. Participants will also
48 be given Consumer Medicines Information (CMI) sheets on the study medicines and a lozenge
49
50
51
52
53
54
55
56
57
58
59
60

22/04/2020 V6

14

1
2
3 instruction sheet highlighting key information on the dosing regimen and common adverse
4
5 effects.
6
7
8
9

10 All study medicines (varenicline and the lozenges) will be initially given for a duration of 12
11 weeks. An additional 12 weeks course of the study medicines (varenicline and the lozenges)
12 will be provided to participants who have ceased smoking during the initial course of treatment
13 and are undergoing concurrent counselling (e.g. Quitline) for smoking cessation. At week 11
14 of treatment, RAs will contact participants in both treatment arms via telephone. At this time-
15 point, participants who self-report continuous abstinence (i.e. smoking no more than 5
16 cigarettes between week-2 and week-11 of treatment) will be offered an additional 12 weeks
17 of treatment using the same study medications. Participants will also be asked about their use
18 of the Quitline service since the start of the study. The decision to provide the additional course
19 of treatment will be at the discretion of a clinician at the recruiting site based on the
20 participant's nicotine dependence, adherence to treatment, any adverse effects they may have
21 experienced during the initial course and their severity. Additional supplies of the trial
22 medications will be delivered to the participant's home by post or pick-up will be arranged
23 from the recruiting hospital.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Control arm

46 Participants randomised to the control group will receive varenicline plus placebo (mint)
47 lozenges. Varenicline will be used at the standard dose as follows: 0.5mg once daily on days
48 1-3, 0.5mg twice daily on days 4-7 and 1mg twice daily from day 8 onwards for 11 weeks.
49 Participants who continue with an additional 12-week course of varenicline will be advised to
50 continue with the standard maintenance dose of 1mg twice daily for this period as
51 recommended in the Product Information Sheet for Champix (36).
52
53
54
55
56
57
58
59
60

22/04/2020 V6

15

Intervention arm

Participants randomised to the intervention arm will receive varenicline plus NRT lozenges.

Varenicline will be used at the standard dose as in the control arm.

NRT/Placebo lozenge dosing schedule (37)

Lozenges will be used by participants only when there is an urge to smoke. Participants will be advised to use a lozenge (2mg) as required when they have an urge to smoke (up to every 1-2 hours initially) and not to use more than 15 lozenges in a day. Participants will also be advised on how to use the lozenges as per the points below:

1. Place one lozenge on the tongue and suck until the taste becomes strong
2. Park the lozenge between the gum and cheek
3. When the taste fades start sucking the lozenge again
4. Repeat this process until the lozenge completely dissolves (it takes about 30 minutes)

Quitline support and text messages

All participants (both intervention and control) will be encouraged to use behavioural support from Quitline as per Quitline standard protocols. However, using Quitline support is not a compulsory requirement for participation in the study.

A Quitline referral form will be completed on behalf of the participant by the RA and sent to Quitline following the baseline interview. Quitline staff will contact the participant in the first instance at a suitable time noted on the referral form. Quitline staff will make a total of four attempts to contact the participant. If a participant is unreachable, Quitline will notify the RA

22/04/2020 V6

16

1
2
3 at the respective site. The RA will follow this up with the participant at the next scheduled
4
5 follow-up (1 or 3 weeks).
6
7
8
9

10 Automated text messages will be sent to all participants by Quitline using their standard
11
12 procedures i.e. once a week for the first month of treatment, then once every month. Text
13
14 messages will reinforce the importance of adherence to the study medicines to increase
15
16 abstinence and also contain emergency contact details for the participants. Participants who do
17
18 not have a mobile phone will be called (with their permission) on their home phone by the RA
19
20 instead of sending text messages.
21
22
23
24
25

26 **Concomitant treatment**

27
28 Participants will be able to take any other medicines as required, except for smoking cessation
29
30 medicines, after discussing with the prescriber of their involvement in the trial. Use of
31
32 concomitant medicines will be assessed and recorded at each follow-up and verification of any
33
34 potential interactions with the study medicines will be carried out. The use of other smoking
35
36 cessation medicines including other forms of NRT (e.g. patches) will be strongly discouraged
37
38 during the course of the study. If a participant uses other smoking cessation medicines during
39
40 the study period, an appropriate record of this will be maintained. Data from such participants
41
42 will still be included in the primary and secondary analyses, however sensitivity analysis will
43
44 be performed after excluding them from the primary analysis.
45
46
47
48
49
50

51 **Data Collection and follow-up**

52
53 Baseline data will be collected at the time of recruitment. All participants will be followed up
54
55 for a period of 12 months after treatment initiation. Five follow-up interviews will be
56
57 conducted: at weeks one and three of treatment and at three, six and twelve months after the
58
59
60

22/04/2020 V6

17

1
2
3 start of treatment. The first and second follow-ups will be done by the RA and will be conducted
4 face-to-face for participants who are still inpatients, or via telephone for participants who have
5 been discharged. Three-, six- and twelve- month follow-ups will be conducted via telephone
6 by a RA, who is blinded to treatment allocation and who was not involved in participant
7 recruitment. Participants unable to be contacted for follow-ups will be considered as “smokers”
8 according to the Russell Standard (38).
9

10
11
12
13
14
15
16
17
18
19 General demographics including age, gender, ethnicity, highest level of education, employment
20 status and possession of any health care card (allowing subsidised health services and
21 medications for the cardholders) will be collected at baseline. Medical and medication history
22 will be obtained from the patients’ hospital notes. Smoking-related information such as current
23 smoking status, age at smoking onset, environmental triggers to smoking and previous attempts
24 at smoking cessation will also be gathered. In addition to this, the study will employ the
25 following validated scales:
26
27
28
29
30
31
32
33

- 34
35 ● **Heaviness of Smoking Index (HSI):** the two item scale measures nicotine dependence
36 and considers time to the first cigarette of the day and the number of cigarettes smoked
37 per day (39).
38
- 39
40 ● **Patient Health Questionnaire (PHQ-9):** this nine-item scale will be used to measure
41 and monitor symptoms of depression amongst participants. Each item will be scored on
42 a four point scale ranging from ‘not at all’ to ‘nearly every day’(40).
43
44
- 45
46 ● **Visual analogue scales** to assess the participants’ level of motivation and confidence
47 to quit smoking: a 10-point numerical scale with one being ‘very low’ to 10 being ‘very
48 high’ will be used for participants to self-report their motivation and confidence to quit
49 smoking.
50
51
52
53
54
55
56
57
58
59
60

18

- **Mood and physical symptoms scale (MPSS):** This questionnaire assesses the severity of withdrawal symptoms and the strengths and frequencies of patients' urges to smoke. The MPSS involves 5-point ratings of depressed mood, irritability, restlessness, difficulty concentrating and hunger and 6-point ratings of strength of urges to smoke and time spent with urges (41).
- **Tool for adherence behaviour screening (TABS):** This is an 8-item tool that assesses both intentional and unintentional non-adherence, participants rate each adherence behaviour statement on a 5-point scale ranging from 'always' to 'never' (42).

Blinding

Three-, six- and twelve- month follow-ups will be conducted by a RA blinded to treatment allocation. Any accidental unblinding will be documented and reported.

Primary endpoints

The primary endpoint is biochemically verified continuous abstinence from 2 weeks to 6 months after treatment initiation. A 2-week period will be allowed on treatment commencement to match the recommended grace period in the varenicline Product Information Sheet (35). Participants who self-report continuous abstinence (i.e. self-report of having smoked no more than five cigarettes, including the use of non-combustible tobacco products and electronic cigarettes) over this period (i.e. weeks 2- 26) will be asked to perform a carbon monoxide (CO) breath test. CO levels will be measured by a trained RA blinded to treatment allocation, using a handheld piCO+ Smokerlyzer (Bedfont Scientific, Maidstone, Kent, UK) during a hospital or home visit. All CO breath testing will be scheduled as soon as is possible (within 1 week) after self-report of abstinence has been recorded. Participants with a CO level <10 ppm will be considered abstinent (18, 43). Sensitivity analysis will be performed using a lower CO cut-off of <5ppm (44).

22/04/2020 V6

19

Secondary endpoints

The secondary outcomes are:

- 1) Participant self-reported continuous abstinence from 2 weeks to three, six and twelve months after treatment initiation
- 2) CO verified continuous abstinence from 2 weeks to 12 months after treatment initiation for participants who self-report abstinence at this follow-up
- 2) Self-reports of withdrawal symptoms and cravings
- 3) Self-reports of adherence to varenicline treatment measured using the TABS
- 4) Self-reports of the number of lozenges consumed per day (NRT or placebo)
- 5) Change in psychological distress
- 6) Adverse events experienced from the study medicines
- 7) Number of Quitline sessions attended/received (self-reported and data transfer from Quitline)
- 8) Self-reported utilisation of other smoking cessation therapies and alternative products (e.g. electronic cigarettes)
- 9) Self-reported 7-day point prevalence abstinence (i.e. smoking not even a puff in the past 7 days on the day of follow-up) at 3, 6 and 12 months after treatment initiation
- 10) CO verified 7-day point prevalence abstinence at 6 and 12 months after treatment initiation for participants who self-report abstinence at these follow-ups

Withdrawal criteria

All participants are strongly encouraged to complete the study, however there may be situations where withdrawal from the study may be appropriate. Participants may withdraw from the study if one or more of the following occur:

22/04/2020 V6

20

- The participant experiences any serious adverse event (SAE) from the use of the study medicines. Prior to treatment discontinuation, input from the treating medical team and Data Safety and Monitoring Board (DSMB) will be sought in establishing the association between treatment exposure and adverse events. The DSMB will review all such cases and make the final judgement on causality.
- If a female participant becomes pregnant during the course of treatment
- If a participant's health status changes significantly and the study medications are no longer in the best interest of the participant
- The lead investigators or health professionals perceive, for any reason, that the study is no longer in the best interest of the participant
- A participant may be withdrawn from the study if he/she wants to do so. Participants are free to withdraw from the study at any time without providing any reason or being disadvantaged.

A participant wishing to withdraw from the study will be asked to complete a 'withdrawal form' for record purposes, but it is not mandatory. Once withdrawn from the study, the participant will not be contacted for further data collection, however the available data will be included in the intention-to-treat analysis. If withdrawal is the result of an adverse drug reaction, the participants will be followed until the adverse reaction resolves or when they return to clinically acceptable medical status.

Sample size

To show an absolute difference of 15% in continuous abstinence rate between study arms (estimate based on continuous abstinence rates in varenicline-NRT trials)(21) at the 5% level of significance with 80% power, we will need 160 subjects per arm. A total of 320 participants will be recruited from the five hospitals, i.e. 64 subjects from each hospital, 32 each in

22/04/2020 V6

21

varenicline monotherapy and varenicline + NRT arms. The primary analysis will be by ITT and participants lost to follow-up will be regarded as smokers (38).

Data analysis

The distribution of data will be assessed and analysed using appropriate statistical tests. Baseline demographic and clinical characteristics will be summarised using counts and proportions, mean and standard deviation or median and interquartile range, according to data type and distribution.

As recommended by the Russell Standard, all randomised patients will be accounted for in the ITT analysis (38). Participants with missing outcomes at follow-up, or whose self-reported abstinence was not biochemically validated will be considered as smokers. Sensitivity analyses using multiple imputation methods will also be carried out. Deceased participants will be excluded from analyses. In a supportive analysis of the primary efficacy endpoint, an analysis will also be conducted on the per protocol set, which excludes patients with any major protocol deviations. Use of NRT after admission to the hospital will be captured and adjusted for in the analysis. Additional unadjusted and adjusted analyses will be performed with analysis by medication status (additional medication given or not given) as a covariate and an interaction of the intervention with this covariate. The statistical analysis plan will be finalised to provide a detailed description of all the analyses prior to locking of the database.

Continuous abstinence at six and twelve months in each treatment arm will be estimated.

Differences between arms and the corresponding 95% confidence interval will be determined.

Primary analysis will be performed using a cut-off CO of <10ppm and additional sensitivity analysis will be conducted using a lower cut-off of <5ppm (44). Logistic regression models

22/04/2020 V6

22

1
2
3 will be used to examine the efficacy of intervention on the primary outcome, after testing
4
5 homogeneity between hospitals using a random effects meta-analysis. In the event of
6
7 heterogeneity, generalised estimating equation models incorporating clustering by hospital
8
9 will be fitted. The effect of intervention on continuous abstinence at 6 and 12 months will be
10
11 tested in pre-specified subgroups (per hospital, nicotine dependence, highly motivated versus
12
13 moderately motivated smokers and men versus women) using models fitted for each
14
15 subgroup containing main effects for intervention and subgroup and an interaction between
16
17 them. Statistical significance will be set at a two-sided p value of 0.05.
18
19
20
21
22

23
24 All randomised participants who take at least one dose of the treatment medications will be
25
26 included in the safety analysis. A chi-squared test or Fisher's exact test as appropriate will be
27
28 used to compare the frequency of treatment withdrawal between the intervention and control
29
30 groups. The number of participants discontinuing treatment prematurely for any reason will be
31
32 summarised by treatment group and by reasons for discontinuation.
33
34
35
36

37
38 The incidence of all suspected adverse events will be summarised by treatment group under
39
40 the following categories: type, severity, action taken and outcome. Adverse event reports
41
42 detailing the relationship of all adverse events that occur in response to the study medication
43
44 will also be prepared. Severity of adverse events will be reported using the Common
45
46 Terminology Criteria for Adverse Events (CTCAE) grading scale (v5.0). The causality of the
47
48 adverse events will be determined using the Naranjo algorithm (45).
49
50
51
52

53 **Data safety and monitoring board (DSMB)**

54
55 To ensure the safety of the study participants and protect the scientific integrity of the trial, a
56
57 three-member independent DSMB together with a study statistician has been established. The
58
59
60

22/04/2020 V6

23

1
2
3 DSMB will periodically review trial safety and outcome data and make recommendations
4 regarding the continuation of the trial based on this information. All serious adverse events
5 (SAEs) will be adjudicated by an end point evaluation committee, which reviews
6 documentation related to the SAE and decides regarding its potential causal relationship with
7 the study drug. Suspected SAEs are also reported as required to the ethics committee of the
8 hospital which enrolled the participant, the human research ethics committee of Monash
9 University, and to the study sponsor. Treatment will be discontinued if there are SAEs or safety
10 concerns relating to the use of the study medicines. Any support necessary to those affected or
11 concerned will be provided independent of the study.
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **ETHICS AND DISSEMINATION**

27
28
29 The trial will be conducted in compliance with the protocol, the principles of Good Clinical
30 Practice (GCP), the National Health and Medical Research Council (NHMRC) National
31 Statement on Ethical Conduct in Human Research (updated 2015) and the Australian Code for
32 the Responsible Conduct of Research (2018). Approval has been obtained from the Human
33 Ethics Committees of all the participating hospitals and the University. Written informed
34 consent will be obtained from each participant at the time of recruitment.
35
36
37
38
39
40
41
42
43
44

45 Both varenicline and NRT have well established safety and efficacy when used appropriately.
46 However, participant safety may still be a concern, especially in combination. Any potential
47 concerns regarding eligibility will be discussed with the treating medical team. Participants in
48 both arms will be closely monitored for any adverse effects.
49
50
51
52
53
54
55

56 All identifiable data will be stored securely, in locked filing cabinets and/or password
57 protected computers at the participating hospital sites or at Monash University. Collected data
58
59
60

22/04/2020 V6

24

1
2
3 will be de-identified, entered into an electronic database and saved on password-protected
4 computers. Participants will receive their CO breath test result immediately after testing. After
5
6 data analysis, a summary of findings will be sent to participants who requested this information.
7
8 The research team will submit study findings to peer-reviewed journals. Any protocol changes
9
10 will be updated on the ANZ Clinical Trials Registry.
11
12
13
14
15
16

17 **PATIENT AND PUBLIC INVOLVEMENT**

18
19 This research will be done without patient or public involvement. Patients and the public will
20
21 not be invited to comment on the study design and will not be consulted to develop patient
22
23 relevant outcomes, interpret the results or contribute to the writing or editing of study
24
25 documents for readability or accuracy.
26
27
28
29

30 **DISCUSSION**

31
32
33 Abstinence rates are suboptimal despite the wide availability of various smoking cessation
34
35 therapies (4). A significant number of quit attempts result in failure; despite this no new
36
37 smoking cessation medication has been approved by the Food and Drugs Administration since
38
39 varenicline in 2006 (11). Effective combinations of existing smoking cessation therapies are
40
41 thus needed to further boost abstinence rates.
42
43
44
45
46

47 This is the first multi-centre, placebo-controlled, randomised controlled trial to evaluate the
48
49 efficacy and safety of a combination of varenicline with acute release forms of NRT. This is
50
51 also the first pragmatic trial to explore the effectiveness of this combination treatment in
52
53 achieving long-term abstinence rates among inpatients in Australian hospitals. Varenicline has
54
55 proven to be one of the most effective smoking cessation therapies, however current literature
56
57 suggests that it may not completely attenuate nicotine cravings. This effect could be overcome
58
59
60

22/04/2020 V6

25

1
2
3 by the addition of an acute release form of NRT (11, 20). If effective this combination treatment
4
5 may help to further boost abstinence rates and the results of this trial could help guide future
6
7 smoking cessation treatments and guidelines. Smoking is banned in the premises of all the
8
9 participating hospitals. This smoke-free environment will help to promote smoking cessation
10
11 in both the intervention and the control arms of the study.
12
13
14

15
16
17 Some strengths of the current study include the randomisation of participants to the intervention
18
19 and control arms reducing selection bias and outcome assessment by staff blinded to treatment
20
21 allocation. The multi-centre design of the trial will ensure that the study sample is
22
23 representative of the inpatient smokers who are admitted to Australian public hospitals. It will
24
25 also enable greater generalisability of the study findings. Furthermore, biochemical verification
26
27 of abstinence used in this trial will enable us to make accurate inferences regarding the
28
29 effectiveness of the intervention. According to standard practices, public hospitals in Australia
30
31 offer NRT to inpatient smokers on admission to help them to abide to the hospital's smoke-
32
33 free policy. As a result, some participants may already be using NRT (e.g. patch) when they
34
35 are recruited. This may affect the participant's initial response to the study medication and
36
37 would be one of the potential limitations of this study. Use of NRT after admission to the
38
39 hospital will be captured and adjusted for in analysis.
40
41
42
43
44
45
46

47 **TRIAL STATUS**

48
49 This trial is registered with the Australia and New Zealand Clinical Trials Registry
50
51 (ACTRN12618001792213). Approval will be sought from the Human Research Ethics
52
53 Committees of all the participating hospitals and Monash University.
54
55
56
57

58 **AUTHORS' CONTRIBUTIONS**

59
60
22/04/2020 V6

26

JG conceived the research idea and developed it with input from other chief investigators, MA, BB, MD, BS, AW and secured research funding. The CIs developed the study in collaboration with GW, SK, OR and AV. RKG is a PhD scholar under the supervision of JG, MA and BB coordinating all the project activities. All the investigators (RKG, MA, BB, GW, MD, BS, AV, AW, SK, DT, AM, RG, EP, JP, DM, LC, ZK, OR, PL, JG) contributed to all phases of the protocol development and finalisation of the manuscript. All authors have reviewed this manuscript and have approved the final protocol.

FUNDING

This study is supported by the Global Research Awards for Nicotine Dependence 2017, an independently-reviewed competitive grants program supported by Pfizer.

COMPETING INTERESTS

Michael Abramson, Billie Bonevski and Johnson George have held investigator-initiated grants from Boehringer Ingelheim (BI) Pty Ltd for an unrelated project. Michael Abramson has also received assistance with conference attendance and conducted an unrelated consultancy for Sanofi. He has also received a speaker's fee from GSK. Johnson George has received honorarium from GSK and Pfizer for consultancy and educational grants for unrelated projects.

REFERENCES

1. Weiland T, Jelinek GA, Taylor SE, Taylor DM. Tobacco smoking by adult emergency department patients in Australia: a point-prevalence study. *Public Health Res Pract.* 2016;26(3).
2. Drope Jeffrey SN, Zachary Cahn, Drope Jacqui, Hamill Stephen, Islami Farhad, Liber Alex, Nigar Nargis, Stoklosa Michal. *The Tobacco Atlas.* Atlanta, Georgia 30303 USA: American Cancer Society, Inc.; 2018 2018.
3. Greenhalgh EM, Bayly M, Winstanley MH. 1.3 Prevalence of smoking—adults Melbourne: Cancer Council Victoria; 2019 [updated February 2019. Available from: <https://www.tobaccoinaustralia.org.au/1-3-prevalence-of-smoking-adults#x2>.
4. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev.* 2013(5).
5. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev.* 2016(5).
6. Jimenez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. *Drugs.* 2009;69(10):1319-38.
7. Wadgave U, Nagesh L. Nicotine Replacement Therapy: An Overview. *Int J Health Sci (Qassim).* 2016;10(3):425-35.
8. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. *Annu Rev Pharmacol Toxicol.* 2009;49:57-71.
9. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. *Cochrane Database Syst Rev.* 2018(5).
10. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev.* 2013(5).
11. Berg KM, Jorenby DE, Baker TB, Fiore MC. Triple Smoking Cessation Therapy with Varenicline, Nicotine Patch and Nicotine Lozenge: A Pilot Study to Assess Tolerability, Satisfaction and End-of-Treatment Quit Rates. *J Smok Cessat.* 2017;13(3):145-53.
12. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. *Nicotine Tob Res.* 2012;14(3):343-50.
13. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. *Circulation.* 2016;133(1):21-30.
14. Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. *Clin Ther.* 2011;33(4):465-77.
15. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev.* 2016(5):CD006103.
16. Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer? *Drugs.* 2010;70(6):643-50.
17. Cinciripini PM, Minnix JA, Green CE, Robinson JD, Engelmann JM, Versace F, et al. An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. *Addiction.* 2018.
18. Thomas D, Farrell M, McRobbie H, Tutka P, Petrie D, West R, et al. The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial. *Addiction.* 2019;114(5):923-33.

19. Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer? *Drugs*. 2010;70(6):643-50.
20. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. *BMC Med*. 2014;12:172.
21. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. *JAMA*. 2014;312(2):155-61.
22. Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. *BMC Public Health*. 2015;15:689.
23. Ray LA, Lunny K, Bujarski S, Moallem N, Krull JL, Miotto K. The effects of varenicline on stress-induced and cue-induced craving for cigarettes. *Drug Alcohol Depend*. 2013;131(1-2):136-42.
24. Grace C. 15.7 Legislation to ban smoking in public spaces. Melbourne: Cancer Council Victoria; 2016 [updated October 2016. Available from: <http://www.tobaccoinaustralia.org.au/chapter-15-smokefree-environment/15-7-legislation>.
25. Rigotti NA, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. *Cochrane Database Syst Rev*. 2007(3):CD001837.
26. Pelletier JH, Strout TD, Baumann MR. A systematic review of smoking cessation interventions in the emergency setting. *Am J Emerg Med*. 2014;32(7):713-24.
27. Murray RL, Leonardi-Bee J, Marsh J, Jayes L, Li J, Parrott S, et al. Systematic identification and treatment of smokers by hospital based cessation practitioners in a secondary care setting: cluster randomised controlled trial. *BMJ*. 2013;347:f4004.
28. Rigotti NA, Munafo MR, Stead LF. Smoking Cessation Interventions for Hospitalized Smokers: A Systematic Review. *Arch Intern Med*. 2008;168(18):1950-60.
29. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. *Chest*. 2007;131(2):446-52.
30. Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. *Cochrane Database Syst Rev*. 2012;5(5):Cd001837.
31. Mendelsohn C. Managing nicotine dependence in NSW hospitals under the Smoke-free Health Care Policy. *Public Health Res Pract*. 2015;25(3):e2531533.
32. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *Jama*. 2006;296(1):47-55.
33. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *Jama*. 2006;296(1):56-63.
34. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *Jama*. 2006;296(1):64-71.
35. Pfizer Australia Pty Ltd. Product information. Champix (as varenicline tartrate). .
36. Pfizer. Australian product information - Champix (varenicline as tartrate). 2015.
37. Novartis Consumer Health GmbH. Package leaflet: information for the user. Nicotinell mint 1mg compressed lozenge.
38. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction*. 2005;100(3):299-303.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
39. Borland R, Yong HH, O'Connor RJ, Hyland A, Thompson ME. The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study. *Nicotine Tob Res.* 2010;12 Suppl:S45-50.
40. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med.* 2001;16(9):606-13.
41. West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. *Psychopharmacology (Berl).* 2004;177(1-2):195-9.
42. George J, Mackinnon A, Kong DC, Stewart K. Development and validation of the Beliefs and Behaviour Questionnaire (BBQ). *Patient Educ Couns.* 2006;64(1-3):50-60.
43. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. *Nicotine Tob Res.* 2002;4(2):149-59.
44. Perkins KA, Karelitz JL, Jao NC. Optimal carbon monoxide criteria to confirm 24-hr smoking abstinence. *Nicotine Tob Res.* 2013;15(5):978-82.
45. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther.* 1981;30(2):239-45.

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

	Reporting Item	Page Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	4 & 25
2				
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial Registration Data Set	n/a
7				
8	data set			
9				
10				
11				
12	Protocol version	#3	Date and version identifier	1
13				
14				
15	Funding	#4	Sources and types of financial, material, and other support	26
16				
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	26
21				
22	responsibilities:			
23				
24	contributorship			
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	26
29				
30	responsibilities:			
31				
32	sponsor contact			
33				
34	information			
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	n/a
39				
40	responsibilities:			
41				
42	sponsor and funder			This is an investigator-initiated trial. The study is supported by a grant awarded by the Global Research Awards for Nicotine dependence 2017.
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58	Roles and	#5d	Composition, roles, and responsibilities of	23
59				
60				

responsibilities: the coordinating centre, steering committee,
 committees endpoint adjudication committee, data
 management team, and other individuals or
 groups overseeing the trial, if applicable (see
 Item 21a for data monitoring committee)

Introduction

Background and [#6a](#) Description of research question and 5
 rationale justification for undertaking the trial, including
 summary of relevant studies (published and
 unpublished) examining benefits and harms
 for each intervention

Background and [#6b](#) Explanation for choice of comparators 7
 rationale: choice of
 comparators

Objectives [#7](#) Specific objectives or hypotheses 9

Trial design [#8](#) Description of trial design including type of 9
 trial (eg, parallel group, crossover, factorial,
 single group), allocation ratio, and framework
 (eg, superiority, equivalence, non-inferiority,
 exploratory)

Methods:

Participants,
 interventions, and
 outcomes

1	Study setting	#9	Description of study settings (eg, community	9
2			clinic, academic hospital) and list of	
3			countries where data will be collected.	
4				
5			Reference to where list of study sites can be	
6			obtained	
7				
8				
9				
10				
11				
12				
13	Eligibility criteria	#10	Inclusion and exclusion criteria for	10
14			participants. If applicable, eligibility criteria	
15			for study centres and individuals who will	
16			perform the interventions (eg, surgeons,	
17			psychotherapists)	
18				
19				
20				
21				
22				
23				
24				
25	Interventions:	#11a	Interventions for each group with sufficient	13
26			detail to allow replication, including how and	
27	description		when they will be administered	
28				
29				
30				
31				
32				
33	Interventions:	#11b	Criteria for discontinuing or modifying	20
34			allocated interventions for a given trial	
35	modifications		participant (eg, drug dose change in	
36			response to harms, participant request, or	
37			improving / worsening disease)	
38				
39				
40				
41				
42				
43				
44				
45	Interventions:	#11c	Strategies to improve adherence to	15
46			intervention protocols, and any procedures	
47	adherence		for monitoring adherence (eg, drug tablet	
48			return; laboratory tests)	
49				
50				
51				
52				
53				
54				
55	Interventions:	#11d	Relevant concomitant care and interventions	16 and 18
56			that are permitted or prohibited during the	
57	concomitant care			
58				
59				
60				

1		trial	
2			
3			
4	Outcomes	#12 Primary, secondary, and other outcomes,	18
5		including the specific measurement variable	
6		(eg, systolic blood pressure), analysis metric	
7		(eg, change from baseline, final value, time	
8		to event), method of aggregation (eg,	
9		median, proportion), and time point for each	
10		outcome. Explanation of the clinical	
11		relevance of chosen efficacy and harm	
12		outcomes is strongly recommended	
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25	Participant timeline	#13 Time schedule of enrolment, interventions	n/a
26		(including any run-ins and washouts),	
27		assessments, and visits for participants. A	a schematic diagram has
28		schematic diagram is highly recommended	not been provided
29		(see Figure)	however the process of
30			recruitment, treatment
31			initiation and follow-ups
32			is clearly detailed in the
33			protocol
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44	Sample size	#14 Estimated number of participants needed to	21
45		achieve study objectives and how it was	
46		determined, including clinical and statistical	
47		assumptions supporting any sample size	
48		calculations	
49			
50			
51			
52			
53			
54			
55			
56			
57	Recruitment	#15 Strategies for achieving adequate participant	11
58			
59			
60			

enrolment to reach target sample size

Methods:

Assignment of interventions (for controlled trials)

Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	12
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	12
Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	12 & 13
Blinding (masking)	#17a	Who will be blinded after assignment to	18

1		interventions (eg, trial participants, care	
2		providers, outcome assessors, data	
3		analysts), and how	
4			
5			
6			
7			
8	Blinding (masking):	#17b If blinded, circumstances under which	18
9			
10	emergency	unblinding is permissible, and procedure for	
11			
12	unblinding	revealing a participant's allocated	
13			
14		intervention during the trial	
15			
16			
17			
18	Methods: Data		
19			
20	collection,		
21			
22	management, and		
23			
24	analysis		
25			
26			
27			
28	Data collection	#18a Plans for assessment and collection of	16
29			
30	plan	outcome, baseline, and other trial data,	
31			
32		including any related processes to promote	
33			
34		data quality (eg, duplicate measurements,	
35			
36		training of assessors) and a description of	
37			
38		study instruments (eg, questionnaires,	
39			
40		laboratory tests) along with their reliability	
41			
42		and validity, if known. Reference to where	
43			
44		data collection forms can be found, if not in	
45			
46		the protocol	
47			
48			
49			
50			
51	Data collection	#18b Plans to promote participant retention and	16 & 21
52			
53	plan: retention	complete follow-up, including list of any	
54			
55		outcome data to be collected for participants	
56			
57		who discontinue or deviate from intervention	
58			
59			
60			

1		protocols	
2			
3			
4	Data management	#19 Plans for data entry, coding, security, and	24
5			
6		storage, including any related processes to	
7			
8		promote data quality (eg, double data entry;	
9			
10		range checks for data values). Reference to	
11			
12		where details of data management	
13			
14		procedures can be found, if not in the	
15		protocol	
16			
17			
18			
19			
20	Statistics:	#20a Statistical methods for analysing primary and	21
21			
22	outcomes	secondary outcomes. Reference to where	
23			
24		other details of the statistical analysis plan	
25			
26		can be found, if not in the protocol	
27			
28			
29			
30	Statistics:	#20b Methods for any additional analyses (eg,	21-22
31			
32	additional analyses	subgroup and adjusted analyses)	
33			
34			
35	Statistics: analysis	#20c Definition of analysis population relating to	21
36			
37	population and	protocol non-adherence (eg, as randomised	
38			
39	missing data	analysis), and any statistical methods to	
40			
41		handle missing data (eg, multiple imputation)	
42			
43			
44			
45	Methods:		
46			
47	Monitoring		
48			
49			
50			
51	Data monitoring:	#21a Composition of data monitoring committee	21
52			
53	formal committee	(DMC); summary of its role and reporting	
54			
55		structure; statement of whether it is	
56			
57		independent from the sponsor and	
58			
59			
60			

1		competing interests; and reference to where	
2		further details about its charter can be found,	
3		if not in the protocol. Alternatively, an	
4		explanation of why a DMC is not needed	
5			
6			
7			
8			
9			
10	Data monitoring:	#21b Description of any interim analyses and	23
11			
12	interim analysis	stopping guidelines, including who will have	
13		access to these interim results and make the	
14		final decision to terminate the trial	
15			
16			
17			
18			
19			
20	Harms	#22 Plans for collecting, assessing, reporting,	23
21		and managing solicited and spontaneously	
22		reported adverse events and other	
23		unintended effects of trial interventions or	
24		trial conduct	
25			
26			
27			
28			
29			
30			
31			
32	Auditing	#23 Frequency and procedures for auditing trial	n/a
33		conduct, if any, and whether the process will	
34		be independent from investigators and the	
35		sponsor	
36			
37			
38			
39			
40			
41			
42	Ethics and		
43	dissemination		
44			
45			
46			
47	Research ethics	#24 Plans for seeking research ethics committee	23
48		/ institutional review board (REC / IRB)	
49	approval	approval	
50			
51			
52			
53			
54			
55	Protocol	#25 Plans for communicating important protocol	23
56		modifications (eg, changes to eligibility	
57	amendments		
58			
59			
60			

1		criteria, outcomes, analyses) to relevant	
2		parties (eg, investigators, REC / IRBs, trial	
3		participants, trial registries, journals,	
4		regulators)	
5			
6			
7			
8			
9			
10	Consent or assent	#26a Who will obtain informed consent or assent	11
11		from potential trial participants or authorised	
12		surrogates, and how (see Item 32)	
13			
14			
15			
16			
17			
18	Consent or assent:	#26b Additional consent provisions for collection	n/a
19	ancillary studies	and use of participant data and biological	
20		specimens in ancillary studies, if applicable	
21			
22			
23			
24			
25	Confidentiality	#27 How personal information about potential	24
26		and enrolled participants will be collected,	
27		shared, and maintained in order to protect	
28		confidentiality before, during, and after the	
29		trial	
30			
31			
32			
33			
34			
35			
36			
37			
38	Declaration of	#28 Financial and other competing interests for	26
39	interests	principal investigators for the overall trial and	
40		each study site	
41			
42			
43			
44			
45	Data access	#29 Statement of who will have access to the	n/a
46		final trial dataset, and disclosure of	
47		contractual agreements that limit such	
48		access for investigators	
49			
50			
51			
52			
53			
54			
55	Ancillary and post	#30 Provisions, if any, for ancillary and post-trial	20
56	trial care	care, and for compensation to those who	
57			
58			
59			
60			

1			suffer harm from trial participation	
2				
3				
4	Dissemination	#31a	Plans for investigators and sponsor to	23
5				
6	policy: trial results		communicate trial results to participants,	
7				
8			healthcare professionals, the public, and	
9				
10			other relevant groups (eg, via publication,	
11				
12			reporting in results databases, or other data	
13				
14			sharing arrangements), including any	
15				
16			publication restrictions	
17				
18				
19				
20	Dissemination	#31b	Authorship eligibility guidelines and any	n/a
21				
22	policy: authorship		intended use of professional writers	
23				
24				
25	Dissemination	#31c	Plans, if any, for granting public access to	n/a
26				
27	policy: reproducible		the full protocol, participant-level dataset,	
28				
29	research		and statistical code	
30				
31				
32				
33	Appendices			
34				
35				
36	Informed consent	#32	Model consent form and other related	n/a
37				
38	materials		documentation given to participants and	
39				
40			authorised surrogates	
41				
42				
43				
44	Biological	#33	Plans for collection, laboratory evaluation,	n/a
45				
46	specimens		and storage of biological specimens for	
47				
48			genetic or molecular analysis in the current	
49				
50			trial and for future use in ancillary studies, if	
51				
52			applicable	
53				
54				
55				
56				
57				
58				
59				
60				

1 None The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution
2 License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a
3 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

The efficacy and safety of varenicline alone versus in combination with nicotine lozenges for smoking cessation among hospitalised smokers (VANISH): study protocol for a randomised, placebo-controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-038184.R2
Article Type:	Protocol
Date Submitted by the Author:	29-Jul-2020
Complete List of Authors:	Gobarani, Rukshar; Monash University Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety Abramson, Michael; Monash University School of Public Health and Preventive Medicine Bonevski, Billie; The University of Newcastle, School and Medicine and Public Health Weeks, Gregory; Barwon Health, Pharmacy Department Dooley, Michael; Monash University Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety; Alfred Health, Pharmacy Department Smith, Brian; Bendigo Health - Bendigo Hospital Campus, Department of Clinical Epidemiology and Biostatistics Veale, Antony; The Queen Elizabeth Hospital, Department of Respiratory Medicine Webb, Ashley; Frankston Hospital, Department of Anaesthesia and Pain Management Kirsa, Sue; Monash Health, Pharmacy Thomas, Dennis; The University of Newcastle Hunter Medical Research Institute, Priority Research Centre for Healthy Lungs Miller, Alistair; Royal Melbourne Hospital, Respiratory and Sleep Medicine Gasser, Rudi; Barwon Health, Department of General Medicine Paul, Eldho; Monash University School of Public Health and Preventive Medicine; Alfred Health, Clinical Haematology Department Parkinson, Jacqueline; Monash Health, Pharmacy Department Meanger, Darshana; Frankston Hospital, Pharmacy Department Coward, Lisa; Frankston Hospital, Department of Anaesthesia Kopsaftis, Zoe; The Queen Elizabeth Hospital, Respiratory Medicine and Clinical Practice Unit Rofe, Olivia; Eastern Health Foundation, Pharmacy Department Lee, Paula; Eastern Health Foundation, Pharmacy Department George, Johnson; Monash University Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety
Primary Subject Heading:	Smoking and tobacco
Secondary Subject Heading:	Addiction, Public health, Smoking and tobacco

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:	PUBLIC HEALTH, Clinical trials < THERAPEUTICS, PRIMARY CARE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1

2
3 **The efficacy and safety of varenicline alone versus in combination with nicotine**
4 **lozenges for smoking cessation among hospitalised smokers (VANISH): study protocol**
5 **for a randomised, placebo-controlled trial**
6
7
8
9

10 Authors:

11
12 **Miss Rukshar K. Gobarani**, BPharm (Hons), Centre for Medicine Use and Safety, Faculty
13 of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia;

14
15
16 rukshar.gobarani@monash.edu

17
18
19 **Prof Michael J. Abramson**, PhD, FRACP, School of Public Health and Preventive
20 Medicine, Monash University, Melbourne, Victoria, Australia;

21
22 michael.abramson@monash.edu

23
24 **Prof Billie Bonevski**, PhD, School and Medicine and Public Health, University of
25 Newcastle, Callaghan, New South Wales, Australia; billie.bonevski@newcastle.edu.au

26
27
28 **Dr Gregory R. Weeks**, PhD, Pharmacy Department, Barwon Health, Geelong, Victoria,

29
30
31
32
33
34
35 Australia; greg@barwonhealth.org.au

36
37 **Prof Michael J. Dooley**, PhD, Centre for Medicine Use and Safety, Monash University,

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Parkville, Victoria, Australia; Pharmacy Department, The Alfred, Prahran, Victoria,

Australia; M.Dooley@alfred.org.au

Prof Brian J. Smith, MBBS, FRACP, PhD, Dip Clin Epi and Biostats, Bendigo Hospital,

Victoria, Australia; bsmith555@bigpond.com

Dr Antony Veale, MBBS, FRACP, Department of Respiratory Medicine, The Queen

Elizabeth Hospital, Adelaide, Australia; antony.veale@sa.gov.au

Dr Ashley Webb, MBBS (Hons), MPH, FANZCA Department of Anaesthesia and Pain

Management, Peninsula Health, Frankston, Victoria, Australia; AWebb@phcn.vic.gov.au

A/Prof Sue Kirsa, Grad Dip Hosp Pharm, Pharmacy Department, Monash Health, Clayton,

Victoria, Australia; Sue.Kirsa@monash.edu

2

Dr Dennis Thomas, PhD, Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, University of Newcastle, New South Wales, Australia;

dennis.thomas@newcastle.edu.au

Dr Alistair Miller, MBBS, Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia; alistair.miller3@mh.org.au

Dr Rudi Gasser, MBBS, Department of General Medicine, Barwon Health, Geelong, Victoria, Australia; rudig@barwonhealth.org.au

Dr Eldho Paul, PhD, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Clinical Haematology Department, The Alfred, Melbourne, Victoria, Australia; eldho.paul@monash.edu

Ms Jacqueline Parkinson, MPharm, Pharmacy Department, Monash Health, Clayton, Victoria, Australia; Jacqueline.Parkinson@monashhealth.org

Miss Darshana Meanger, BPharm, Grad Cert Pharm Prac, Pharmacy Department, Peninsula Health, Frankston, Victoria, Australia; DMeanger@phcn.vic.gov.au

Ms Lisa Coward, EEN, Department of Anaesthesia, Peninsula Health, Frankston, Victoria, Australia; LCoward@phcn.vic.gov.au

Dr Zoe Kopsaftis, PhD, BHSc (Hons), Respiratory Medicine and Clinical Practice Unit, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Zoe.Kopsaftis@sa.gov.au

Ms Olivia Rofe, BPharm, MPharm (Clin), Prof Cert Health Syst Management, Pharmacy Department, Eastern Health, Melbourne, Victoria, Australia;

Olivia.Rofe@easternhealth.org.au

Ms Paula Lee, BPharm, Grad Dip Clin Res, Pharmacy Department, Eastern Health, Box Hill, Victoria, Australia; Paula.Lee@easternhealth.org.au

3

1
2
3 **Dr Johnson George (corresponding author)**, PhD, Centre for Medicine Use and Safety,
4 Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Victoria,
5 Australia; johnson.george@monash.edu
6
7
8
9

10 11 12 **ABSTRACT**

13
14 **Introduction:** Smoking is a leading cause of premature deaths globally. The health benefits
15 of smoking cessation are many. However, majority of quit attempts are unsuccessful. One
16 way to potentially improve success rates is to evaluate new combinations of existing smoking
17 cessation therapies that may work synergistically to decrease the intensity of withdrawal
18 symptoms and cravings.
19
20
21
22
23
24

25
26 **Aims:** To evaluate the feasibility, efficacy and safety of the combination of varenicline and
27 nicotine replacement therapy (NRT) lozenges versus varenicline alone in assisting
28 hospitalised smokers to quit.
29
30
31
32

33
34 **Methods and analysis:** This is a multi-centre, randomised, placebo-controlled trial. Adults
35 with a history of smoking ≥ 10 cigarettes per day on average in the four weeks prior to their
36 hospitalisation will be recruited. Participants will be randomly assigned to either the
37 intervention group and will receive varenicline and NRT lozenges, or the control group and
38 will receive varenicline and placebo lozenges. All participants will be actively referred to
39 behavioural support from telephone Quitline. Participants are followed up at 1 and 3 weeks
40 and 3, 6 and 12 months from the start of treatment. The primary outcome is carbon monoxide
41 (CO) validated prolonged abstinence from 2 weeks to 6 months after treatment initiation.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Secondary outcomes include self-reported and biochemically validated prolonged and point
prevalence abstinence at 3, 6 and 12 months, self-reported adverse events, withdrawal
symptoms and cravings, adherence to treatment, Quitline sessions attended etc. According to

4

1
2
3 the Russell standard, all randomised participants will be accounted for in the primary
4
5 intention-to-treat analysis.
6
7

8 **Ethics and dissemination:** The trial will be conducted in compliance with the protocol, the
9
10 principles of Good Clinical Practice, the National Health and Medical Research Council
11
12 (NHMRC) National Statement on Ethical Conduct in Human Research (updated 2015) and the
13
14 Australian Code for the Responsible Conduct of Research (2018). Approval will be sought
15
16 from the Human Ethics Committees of all the participating hospitals and the University.
17
18 Written informed consent will be obtained from each participant at the time of recruitment.
19

20
21
22 **Trial registration:** Australia New Zealand Clinical Trials Registry:
23

24
25 ACTRN12618001792213
26
27
28

29 **Strengths and limitations of this study:**
30

- 31 • This is the first multi-centre, randomised, placebo-controlled trial to evaluate the
32 efficacy and safety of a combination of varenicline and an immediate-release form of
33
34 NRT.
35
36
- 37 • This is also the first pragmatic trial exploring the effectiveness of this combination
38
39 treatment in achieving long-term abstinence rates among inpatients in Australian
40
41 hospitals.
42
43
- 44 • The multi-centre pragmatic design of the trial will ensure that the study sample is
45
46 representative of the inpatient smokers who are admitted to Australian public
47
48 hospitals allowing greater generalizability of study findings
49
50
- 51 • Biochemical verification of abstinence used in this trial will enable us to make
52
53 accurate inferences regarding the effectiveness of the intervention.
54
55
56
57
58
59
60

BACKGROUND

Tobacco smoking is one of the leading causes of preventable morbidity and mortality around the world. Representing a key risk factor for deaths due to ischaemic heart disease, stroke and cancer, tobacco smoking kills approximately six million people globally each year.(1) Holding the potential to damage nearly every organ system in the human body, tobacco smoking accounts for 7.8% of the total burden of disease in Australia.(1, 2) Despite this, 14% of adults aged 18 years and over smoked daily in 2017-2018.(2)

Various therapeutic agents are currently available to assist in quitting smoking. A substantial body of research has demonstrated the effectiveness of such therapies in increasing abstinence rates.(3) Of these, varenicline is the most effective single agent for abstinence outcomes. Available as a prescription only medicine in Australia, varenicline at the standard dose more than doubles the chances of quitting compared with placebo (pooled RR for continuous or sustained abstinence at six months or longer 2.24; 95% CI 2.06 to 2.43).(4) It has a dual mechanism of action and exerts its effects by acting as a partial agonist at the $\alpha 4\beta 2$ nicotinic receptors in the brain.(5) This reduces the drop in the mesolimbic dopaminergic levels that occurs during smoking cessation, relieving withdrawal symptoms.(5) Varenicline also antagonises the activity of nicotine on its receptors which prevents the release of neurotransmitters such as dopamine and in doing so reduces feelings of pleasure experienced from a smoking relapse.(5)

Nicotine replacement therapy (NRT) is another first line treatment for those seeking pharmacological help to quitting smoking.(3) NRT replaces some of the nicotine in the blood that was previously derived from cigarettes, without the presence of the thousands of other chemicals that are also produced during tobacco combustion which are largely responsible for

6

causing tobacco-related illnesses.(6, 7) In this manner, NRT decreases the intensity of withdrawal symptoms and cigarette cravings.(6, 7)

In many countries, NRT is available over-the-counter in acute release formulations such as gums, lozenges, inhalers, mouth sprays and sublingual tablets and in slow release forms such as transdermal patches. Transdermal patches release nicotine slowly over a prolonged period of time (24 or 16 hour patches available) whereas, acute release forms of NRT provide a faster release of nicotine in the blood.(6) Acute-dosing products allow the user to titrate both the amount and timing of their doses.(6) Therefore, these forms of NRT can be used as “rescue-medication” by smokers to alleviate cigarette cravings.(6)

NRTs are more effective than placebo in achieving long-term smoking abstinence (RR of abstinence for any form of NRT relative to control 1.55; 95% CI 1.49 to 1.61).(8) Various forms of NRT perform similarly against each other [pooled RRs of 1.64 for nicotine patch (95% CI 1.53 to 1.75); 1.49 for nicotine gum (95% CI 1.40 to 1.60) and 1.52 for oral tablets/lozenges (95% CI 1.32 to 1.74) relative to control], and evidence suggests that the use of two forms of NRT; a slow release formulation with an acute release formulation (i.e. combination NRT) is more effective than using a single form of NRT.(3)

Research to date suggests that varenicline (as monotherapy) and combination NRT are the most effective smoking cessation therapies that are currently available to assist in achieving abstinence.(3) Even these, however, result in only modest increases in abstinence rates of approximately 30-40% at 6 months compared with placebo.(4, 9-11) A substantial amount of research is thus focused on evaluating new treatment options and approaches for smoking cessation to further increase abstinence rates.(12)

7

1
2
3 In attempts to improve smoking cessation rates, new combinations of existing smoking
4 cessation therapies have been evaluated.(13-15) Current research suggests that varenicline may
5 not fully saturate the nicotinic acetylcholine receptors in the brain.(13) This in turn leads to
6 only a partial attenuation of nicotine cravings.(16) It has been postulated that adding NRT to
7 varenicline treatment may therefore increase receptor saturation, which in turn may decrease
8 cigarette cravings more completely.(13, 16)
9

10
11
12 In response to this, studies have evaluated the effectiveness of the combination of varenicline
13 and NRT patches versus varenicline monotherapy on smoking cessation rates, although
14 findings have been equivocal.(16, 17) A systematic review and meta-analysis of three
15 randomised controlled trials demonstrated that the combination of varenicline and NRT patches
16 was associated with significantly higher rates of abstinence versus varenicline alone at the end
17 of treatment i.e. at 12 weeks (OR 1.50; 95% CI 1.14 to 1.97) and at 6 months (OR 1.62; 95%
18 CI 1.18 to 2.23).(18) This association, however, did not exist when the largest of the three
19 trials, which also used a pre-quit nicotine patch, was excluded from the analysis.(18)
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 No studies to date have evaluated the effectiveness of the combination of varenicline and acute
41 release forms of NRT which have proven to be just as effective as NRT patches in assisting
42 smokers to quit.(8) Secondly, steady-state plasma varenicline concentrations are achieved after
43 approximately four days of continued treatment.(13) During this time, patients may experience
44 significant discomfort from withdrawal symptoms and often continue to smoke for several
45 weeks after initiating varenicline therapy.(13) Furthermore, a study reported that while
46 varenicline reduces both tonic and cue-induced cigarette cravings, it does not attenuate cue-
47 induced cravings after stress induction compared to placebo.(19) In such situations, the use of
48 an *ad lib* NRT product in combination with varenicline would thus enable patients to better
49
50
51
52
53
54
55
56
57
58
59
60

8

1
2
3 manage their withdrawal symptoms and cravings particularly to prevent stress and cue-related
4
5 reinstatement of smoking.(13, 19)
6
7
8
9

10 Smoking inside public hospitals and within 4 meters of the entrances to all public hospitals is
11
12 prohibited in Australia.(20) This restriction provides a window of opportunity for the
13
14 implementation of smoking cessation interventions as inpatient smokers are placed away from
15
16 their usual environmental triggers of smoking. During this time of increased vulnerability
17
18 regarding their health, patients may be more motivated to quit and may also be more receptive
19
20 to smoking cessation interventions and a change in behaviour particularly if they are presenting
21
22 with conditions that may be caused or exacerbated by smoking.(21-25)
23
24
25
26
27

28 Furthermore, hospitalised inpatients generally smoke a greater number of cigarettes per day
29
30 than the general population and have a higher level of nicotine dependence.(1, 26) Varenicline
31
32 is a smoking cessation agent that is targeted towards moderate to heavy smokers.(27-29)
33
34 Therefore, this group of patients provide an ideal study population for evaluating the efficacy
35
36 and safety of the combination of varenicline and nicotine lozenges for smoking cessation. In
37
38 addition to this, an inpatient setting allows the trial medications to be commenced and
39
40 administered under clinical supervision of hospital staff. This would ensure that participants
41
42 have immediate access to a healthcare professional for medication education or management
43
44 of an adverse drug event due to any trial medication. This study, therefore, aims to evaluate the
45
46 effectiveness and safety of the combination of varenicline and NRT lozenges versus varenicline
47
48 monotherapy in assisting hospitalised smokers in quitting.
49
50
51
52
53
54
55

56 **Objectives**

57
58
59
60

9

The primary objective of the study is to compare biochemically-verified prolonged abstinence at 6 months in hospitalised smokers treated using varenicline plus NRT lozenges with those treated with varenicline and placebo lozenges.

The secondary objectives of this study are to compare the differences between treatment groups on the following outcomes:

- CO verified prolonged abstinence from 2 weeks to 12 months after treatment initiation for participants who self-report abstinence at the 12-month follow-up
- Self-reported 7-day point prevalence abstinence (smoking not even a puff in the past 7 days on the day of follow-up) at 3, 6 and 12 months after treatment initiation
- Self-reported prolonged abstinence measured from 2 weeks to 3, 6 and 12 months after treatment initiation
- CO verified 7-day point prevalence abstinence at 6 and 12 months after treatment initiation for participants who self-report abstinence at these follow-ups
- Self-reported treatment adherence and adverse events to the study medicines at all follow-ups as well as number of Quitline sessions attended after treatment initiation.

METHODS

Study design

A randomised, placebo-controlled, multi-centre, double blinded study

Setting and Participants

Participants will be recruited from the inpatient wards of five 'smoke-free' public hospitals in Australia. Participants will be screened for eligibility at baseline and written informed consent

10

1
2
3 will be sought. Eligible participants will be randomised to either the intervention or control
4
5 group and will be followed up for 12 months from treatment initiation.
6
7
8
9

10 **Inclusion and Exclusion criteria**

11
12 Patients eligible for the trial are: adults ≥ 18 years, admitted to participating hospitals with a
13
14 history of smoking ≥ 10 cigarettes per day on average in the four weeks prior to their hospital
15
16 admission, interested in quitting smoking, willing to use pharmacotherapy, available for a 12
17
18 months follow-up post-treatment initiation and willing/capable to provide written informed
19
20 consent.
21
22
23

24
25
26 Patients who do not meet all of the above inclusion criteria, those who have a terminal illness
27
28 with an anticipated survival of < 6 months, those who have an unstable cardiovascular status
29
30 (recent myocardial infarction or stroke within the past 3 months) or those with a new diagnosis
31
32 of a major psychiatric illness (e.g. psychosis) within the past 3 months will be excluded from
33
34 the study. Patients unable to provide informed written consent because of their admitting
35
36 medical condition or health status at the time of recruitment (e.g. patients in intensive care unit
37
38 or patients with an acute psychiatric condition) will be excluded from the trial. Patients unable
39
40 to communicate in English and provide written consent will also be excluded given the
41
42 potential need to regularly communicate with the investigators during the entire trial period,
43
44 and the lack of funding for interpreters.
45
46
47
48
49

50
51 Further exclusion criteria for this study are: women who are pregnant, breastfeeding or
52
53 planning to become pregnant in the next 6 months and patients who were already using
54
55 smoking cessation medications or approaches at the time of their hospital admission (i.e. NRT,
56
57 varenicline, bupropion, clonidine, nortriptyline, or electronic nicotine delivering systems). In
58
59
60

11

1
2
3 addition to this, patients who are currently participating in other smoking cessation
4 programs/studies, those who have completed ≥ 12 weeks course of varenicline in the 12 months
5 prior to hospitalisation (these patients may have a higher nicotine dependence and may not
6 respond well to sole varenicline therapy), those who have had intolerable/serious adverse
7 events from the use of varenicline or NRTs in the past, and those who have contraindications
8 for their use (including those using medications known to have major interactions with either
9 varenicline or NRT) will be excluded from the study.
10
11
12
13
14
15
16
17
18
19
20

21 **Participant recruitment**

22
23 Eligible participants will be identified through active screening of hospital records by a trained
24 Research Assistant (RA), a nurse or a pharmacist employed at each site. Ward staff including
25 doctors, nurses, pharmacists and physiotherapists will be informed of the study and asked to
26 refer all patients identified as current smokers to the RA. Flyers containing study information
27 will be displayed in hospital wards to notify inpatients of the study. Flyers will contain the
28 contact information of the RA at the site so that interested patients can discuss the study with
29 them.
30
31
32
33
34
35
36
37
38
39
40
41

42 Once potential participants are identified, the RA in consultation with the treating medical team
43 will assess each patient's eligibility for the study considering their current health status and any
44 apparent contraindications for the use of varenicline or NRT. Details of this initial medical
45 screening will be recorded by the RA. The RA will then approach eligible patients, describe
46 the project to each potential participant, provide a plain language statement and answer any
47 questions. If the patient is interested in participating, written informed consent will be sought
48 before proceeding with the baseline interview.
49
50
51
52
53
54
55
56
57
58
59
60

12

Baseline data collection

Each participant will be assigned a study number and baseline data collected. Data gathered during the interview will include information on the participant's smoking habits, previous attempts at quitting and current willingness/confidence to quit. A detailed medical history (current medical conditions and medications) including the presence of any contraindications or precautions for the use of the study medicines (based on the Product Information Sheets) will be sought. Participants with any exclusion criterion will not be enrolled, and will be referred to Quitline for smoking cessation support. Participants who do not meet any of the exclusion criteria, but who have a specified precaution for the use of the trial medications, will be referred to an in-house clinician for further assessment. The decision on whether to include such participants will be at the discretion of the treating medical team, the RA and the patient based on an evaluation of the potential risks and benefits from participation in the study.

The baseline interview will also involve an assessment of the presence of psychological distress using the Patient Health Questionnaire (PHQ-9). Once baseline data collection is completed, to ensure the safe ongoing delivery of healthcare services to participants, the RA will seek the participants' consent to contact their regular general practitioner (GP) and community pharmacist to inform them of their patient's participation in the study.

Randomisation: allocation concealment and sequence generation

Following the collection of baseline data, participants will be randomised to one of the study arms by a clinical trials pharmacist at each of the five hospitals using a computer-generated randomisation list. Randomisation is stratified by site and random permuted block sizes of two and four will be used. Sealed opaque envelopes will be used for the concealment of treatment allocation. Each site will be provided with 64 envelopes containing group allocation. The

13

1
2
3 clinical trials pharmacist at each site will open the envelopes in a sequential manner when a
4 participant is recruited to identify group allocation. Once a participant's group allocation has
5 been noted along with the study ID, study medicines will be charted on the participant's
6 medication chart by a clinician involved in the study. The clinical trials pharmacist will then
7 dispense the study medicines as stated in the envelope ([varenicline and NRT lozenges] or
8 [varenicline and placebo lozenges]) and hand these to the RA. The RA will then give the
9 medicines to the participant and provide detailed counselling. Participants will not be told
10 whether they are receiving NRT or placebo lozenges. During hospital stay, the nurse in-charge
11 of the ward will be responsible for daily administration of the medicines to the participant
12 according to standard hospital practice. Participants will be asked to notify a nurse when they
13 wish to have a lozenge (NRT or placebo).
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Study arms and medicines**

32
33 Participants randomised to the control group will receive varenicline plus placebo (mint)
34 lozenges while participants randomised to the intervention arm will receive varenicline plus
35 NRT lozenges.
36
37
38
39
40
41

42 Varenicline in both treatment arms will be used at the standard dose as follows: 0.5mg once
43 daily on days 1-3, 0.5mg twice daily on days 4-7 and 1mg twice daily from day 8 onwards for
44 11 weeks.(30) Participants who continue with an additional 12-week course of varenicline will
45 be advised to continue with the standard maintenance dose of 1mg twice daily for this period
46 as recommended in the Product Information Sheet for Champix.(30)
47
48
49
50
51
52
53
54
55

56 *NRT/Placebo lozenge dosing schedule*
57
58
59
60

14

1
2
3 Lozenges will be used by participants only when there is an urge to smoke.(31) Participants
4 will be advised to use a lozenge (2mg) as required when they have an urge to smoke (up to
5 every 1-2 hours initially) and not to use more than 15 lozenges in a day.(31) Participants will
6 also be advised on how to use the lozenges as per the points below:
7
8
9

- 10 1. Place one lozenge on the tongue and suck until the taste becomes strong
 - 11 2. Park the lozenge between the gum and cheek
 - 12 3. When the taste fades start sucking the lozenge again
 - 13 4. Repeat this process until the lozenge completely dissolves (it takes about 30 minutes)
- 14
15
16
17
18
19
20
21
22
23

24 NRT and placebo (mint) lozenges will be repackaged and labelled in sachets containing two
25 2mg lozenges. For the initial supply, participants will be provided with 12 weeks supply of
26 varenicline and 100 sachets of the NRT/placebo lozenges. The number of lozenges used on
27 average per day will be assessed at the 3-week follow-up. Participants who would like
28 additional supplies of the lozenges can have them delivered to their home by post.
29
30
31
32
33
34
35
36
37

38 Participants will be advised to commence the trial medication(s) during their hospital stay. The
39 smoke-free policies of Australian hospitals create an environment conducive for abstinence.
40 However, this does not prevent inpatient smokers from going outside hospital premises for a
41 smoke. Therefore, all participants will be asked to reduce their smoking over the first seven
42 days of varenicline treatment and aim to quit completely within two weeks. Patients will be
43 asked to stop smoking in line with the varenicline Product Information Sheet.(30) The RA
44 involved in recruitment will provide verbal counselling to the participants on the dosing
45 regimen, common adverse effects of the study medicines, who to contact in the event of an
46 emergency, their contact details and how to obtain renewed supplies of trial medications.
47 Participants will also be given Consumer Medicines Information (CMI) sheets on the study
48
49
50
51
52
53
54
55
56
57
58
59
60

15

1
2
3 medicines and a lozenge instruction sheet highlighting key information on the dosing regimen
4
5 and common adverse effects.
6
7
8
9

10 All study medicines (varenicline and the lozenges) will be initially given for a duration of 12
11 weeks. An additional 12 weeks course of the study medicines (varenicline and the lozenges)
12 will be provided to participants who have ceased smoking during the initial course of treatment
13 and are undergoing concurrent counselling (e.g. Quitline) for smoking cessation. At week 11
14 of treatment, RAs will contact participants in both treatment arms via telephone. At this time-
15 point, participants who self-report prolonged abstinence (i.e. smoking no more than 5 cigarettes
16 between week-2 and week-11 of treatment) will be offered an additional 12 weeks of treatment
17 using the same study medications. Participants will also be asked about their use of the Quitline
18 service since the start of the study. The decision to provide the additional course of treatment
19 will be at the discretion of a clinician at the recruiting site based on the participant's nicotine
20 dependence, adherence to treatment, any adverse effects they may have experienced during the
21 initial course and their severity. Additional supplies of the trial medications will be delivered
22 to the participant's home by post or pick-up will be arranged from the recruiting hospital.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Quitline support and text messages**

43
44 All participants (both intervention and control) will be encouraged to use behavioural support
45 from Quitline as per Quitline standard protocols. However, using Quitline support is not a
46 compulsory requirement for participation in the study.
47
48
49
50
51

52
53 A Quitline referral form will be completed on behalf of the participant by the RA and sent to
54 Quitline following the baseline interview. Quitline staff will contact the participant in the first
55 instance at a suitable time noted on the referral form. Quitline staff will make a total of four
56
57
58
59
60

16

1
2
3 attempts to contact the participant. If a participant is unreachable, Quitline will notify the RA
4
5 at the respective site. The RA will follow this up with the participant at the next scheduled
6
7 follow-up (1 or 3 weeks).
8
9

10
11 Automated text messages will be sent to all participants by Quitline using their standard
12
13 procedures i.e. once a week for the first month of treatment, then once every month. Text
14
15 messages will reinforce the importance of adherence to the study medicines to increase
16
17 abstinence and also contain emergency contact details for the participants. Participants who do
18
19 not have a mobile phone will be called (with their permission) on their home phone by the RA
20
21 instead of sending text messages.
22
23
24
25
26
27

28 **Concomitant treatment**

29
30 Participants will be able to take any other medicines as required, except for smoking cessation
31
32 medicines, after discussing with the prescriber of their involvement in the trial. Use of
33
34 concomitant medicines will be assessed and recorded at each follow-up and verification of any
35
36 potential interactions with the study medicines will be carried out. The use of other smoking
37
38 cessation medicines including other forms of NRT (e.g. patches) will be strongly discouraged
39
40 during the course of the study. If a participant uses other smoking cessation medicines during
41
42 the study period, an appropriate record of this will be maintained. Data from such participants
43
44 will still be included in the primary and secondary analyses, however sensitivity analysis will
45
46 be performed after excluding them from the primary analysis.
47
48
49
50
51
52

53 **Data Collection and follow-up**

54
55 Baseline data will be collected at the time of recruitment. All participants will be followed up
56
57 for a period of 12 months after treatment initiation. Five follow-up interviews will be
58
59
60

17

1
2
3 conducted: at weeks one and three of treatment and at three, six and twelve months after the
4 start of treatment. The first and second follow-ups will be done by the RA and will be conducted
5 face-to-face for participants who are still inpatients, or via telephone for participants who have
6 been discharged. Three-, six- and twelve- month follow-ups will be conducted via telephone
7 by a RA, who is blinded to treatment allocation and who was not involved in participant
8 recruitment. Participants unable to be contacted for follow-ups will be considered as “smokers”
9 according to the Russell Standard.(32)

10
11
12
13
14
15
16
17
18
19
20
21
22 General demographics including age, gender, ethnicity, highest level of education, employment
23 status and possession of any health care card (allowing subsidised health services and
24 medications for the cardholders) will be collected at baseline. Medical and medication history
25 will be obtained from the patients’ hospital notes. Smoking-related information such as current
26 smoking status, age at smoking onset, environmental triggers to smoking and previous attempts
27 at smoking cessation will also be gathered. In addition to this, the study will employ the
28 following validated scales:
29
30
31
32
33
34
35
36

- 37 ● ***Heaviness of Smoking Index (HSI)***: the two item scale measures nicotine dependence
38 and considers time to the first cigarette of the day and the number of cigarettes smoked
39 per day.(33)
- 40 ● ***Patient Health Questionnaire (PHQ-9)***: this nine-item scale will be used to measure
41 and monitor symptoms of depression amongst participants. Each item will be scored on
42 a four point scale ranging from ‘not at all’ to ‘nearly every day.’(34)
- 43 ● ***Visual analogue scales*** to assess the participants’ level of motivation and confidence
44 to quit smoking: a 10-point numerical scale with one being ‘very low’ to 10 being ‘very
45 high’ will be used for participants to self-report their motivation and confidence to quit
46 smoking.

18

- **Mood and physical symptoms scale (MPSS):** This questionnaire assesses the severity of withdrawal symptoms and the strengths and frequencies of patients' urges to smoke. The MPSS involves 5-point ratings of depressed mood, irritability, restlessness, difficulty concentrating and hunger and 6-point ratings of strength of urges to smoke and time spent with urges.(35)
- **Tool for adherence behaviour screening (TABS):** This is an 8-item tool that assesses both intentional and unintentional non-adherence, participants rate each adherence behaviour statement on a 5-point scale ranging from 'always' to 'never.'(36)

Blinding

Three-, six- and twelve- month follow-ups will be conducted by a RA blinded to treatment allocation. Any accidental unblinding will be documented and reported.

Primary endpoints

The primary endpoint is biochemically verified prolonged abstinence from 2 weeks to 6 months after treatment initiation. A 2-week period will be allowed on treatment commencement to match the recommended grace period in the varenicline Product Information Sheet.(30) Participants who self-report prolonged abstinence (i.e. self-report of having smoked no more than five cigarettes, including the use of non-combustible tobacco products and electronic cigarettes) over this period (i.e. weeks 2- 26) will be asked to perform a carbon monoxide (CO) breath test. CO levels will be measured by a trained RA blinded to treatment allocation, using a handheld piCO+ Smokerlyzer (Bedfont Scientific, Maidstone, Kent, UK) during a hospital or home visit. All CO breath testing will be scheduled as soon as is possible (within 1 week) after self-report of abstinence has been recorded. Participants with a CO level <6 ppm will be

19

1
2
3 considered abstinent.(15, 37) Sensitivity analysis will be performed using a higher CO cut-off
4
5 of <10ppm.(38)
6
7
8
9

10 **Secondary endpoints**

11 The secondary outcomes are:
12

- 13 1) Participant self-reported prolonged abstinence from 2 weeks to three, six and twelve months
14 after treatment initiation
- 15 2) CO verified prolonged abstinence from 2 weeks to 12 months after treatment initiation for
16 participants who self-report abstinence at this follow-up
- 17 2) Self-reports of withdrawal symptoms and cravings
- 18 3) Self-reports of adherence to varenicline treatment measured using the TABS
- 19 4) Self-reports of the average number of lozenges consumed per day (NRT or placebo) at 3-
20 weeks from treatment initiation
- 21 5) Change in psychological distress measured using the PHQ-9 scale
- 22 6) Adverse events experienced from the study medicines
- 23 7) Number of Quitline sessions attended/received (self-reported and data transfer from
24 Quitline)
- 25 8) Self-reported utilisation of other smoking cessation therapies and alternative products (e.g.
26 electronic cigarettes)
- 27 9) Self-reported 7-day point prevalence abstinence (i.e. smoking not even a puff in the past 7
28 days on the day of follow-up) at 3, 6 and 12 months after treatment initiation
- 29 10) CO verified 7-day point prevalence abstinence at 6 and 12 months after treatment initiation
30 for participants who self-report abstinence at these follow-ups
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 **Withdrawal criteria**

20

All participants are strongly encouraged to complete the study, however there may be situations where withdrawal from the study may be appropriate. Participants may withdraw from the study if one or more of the following occur:

- The participant experiences any serious adverse event (SAE) from the use of the study medicines. Prior to treatment discontinuation, input from the treating medical team and Data Safety and Monitoring Board (DSMB) will be sought in establishing the association between treatment exposure and adverse events. The DSMB will review all such cases and make the final judgement on causality.
- If a female participant becomes pregnant during the course of treatment
- If a participant's health status changes significantly and the study medications are no longer in the best interest of the participant
- The lead investigators or health professionals perceive, for any reason, that the study is no longer in the best interest of the participant
- A participant may be withdrawn from the study if he/she wants to do so. Participants are free to withdraw from the study at any time without providing any reason or being disadvantaged.

A participant wishing to withdraw from the study will be asked to complete a 'withdrawal form' for record purposes, but it is not mandatory. Once withdrawn from the study, the participant will not be contacted for further data collection, however the available data will be included in the intention-to-treat analysis. If withdrawal is the result of an adverse drug reaction, the participants will be followed until the adverse reaction resolves or when they return to clinically acceptable medical status.

Sample size

21

In a previous trial of hospitalised smokers with high nicotine dependence, the long-term abstinence rate in the usual care and intervention groups were 8.5 – 10%, respectively.(39) Modelling continuous abstinence rates over time from clinical trials of varenicline found that, at 52 weeks, abstinence rates were 22.5% for varenicline and 8.3% for placebo.(40) To show an absolute difference of 15% in prolonged abstinence rate between study arms (estimate based on abstinence rates in varenicline-NRT trials),(17) at the 5% level of significance with 80% power, we will need 160 subjects per arm. A total of 320 participants will be recruited from the five hospitals, i.e. 64 subjects from each hospital, 32 each in varenicline monotherapy and varenicline + NRT arms. The primary analysis will be by ITT and participants lost to follow-up will be regarded as smokers.(32)

Data analysis

The distribution of data will be assessed and analysed using appropriate statistical tests. Baseline demographic and clinical characteristics will be summarised using counts and proportions, mean and standard deviation or median and interquartile range, according to data type and distribution.

As recommended by the Russell Standard, all randomised patients will be accounted for in the ITT analysis.(32) Participants with missing outcomes at follow-up, or whose self-reported abstinence was not biochemically validated will be considered as smokers. Sensitivity analyses using multiple imputation methods will also be carried out. Deceased participants will be excluded from analyses. In a supportive analysis of the primary efficacy endpoint, an analysis will also be conducted on the per protocol set, which excludes patients with any major protocol deviations. Use of NRT after admission to the hospital will be captured and adjusted for in the analysis. Additional unadjusted and adjusted analyses will be performed with analysis by

22

1
2
3 medication status (additional medication given or not given) as a covariate and an interaction
4
5 of the intervention with this covariate. The statistical analysis plan will be finalised to provide
6
7 a detailed description of all the analyses prior to locking of the database.
8
9

10
11
12 Prolonged abstinence at six and twelve months in each treatment arm will be estimated.

13
14 Differences between arms and the corresponding 95% confidence interval will be determined.

15
16 Primary analysis will be performed using a cut-off CO of <6ppm and additional sensitivity
17
18 analysis will be conducted using a higher cut-off of <10ppm.(38) Logistic regression models
19
20 will be used to examine the efficacy of intervention on the primary outcome, after testing
21
22 homogeneity between hospitals using a random effects meta-analysis. In the event of
23
24 heterogeneity, generalised estimating equation models incorporating clustering by hospital
25
26 will be fitted. The effect of intervention on prolonged abstinence at 6 and 12 months will be
27
28 tested in pre-specified subgroups (per hospital, nicotine dependence, highly motivated versus
29
30 moderately motivated smokers and men versus women) using models fitted for each
31
32 subgroup containing main effects for intervention and subgroup and an interaction between
33
34 them. Statistical significance will be set at a two-sided p value of 0.05.
35
36
37
38
39
40
41

42
43 All randomised participants who take at least one dose of the treatment medications will be
44
45 included in the safety analysis. A chi-squared test or Fisher's exact test as appropriate will be
46
47 used to compare the frequency of treatment withdrawal between the intervention and control
48
49 groups. The number of participants discontinuing treatment prematurely for any reason will be
50
51 summarised by treatment group and by reasons for discontinuation.
52
53

54
55
56 The incidence of all suspected adverse events will be summarised by treatment group under
57
58 the following categories: type, severity, action taken and outcome. Adverse event reports
59
60

23

1
2
3 detailing the relationship of all adverse events that occur in response to the study medication
4
5 will also be prepared. Severity of adverse events will be reported using the Common
6
7 Terminology Criteria for Adverse Events (CTCAE) grading scale (v5.0). The causality of the
8
9 adverse events will be determined using the Naranjo algorithm.(41)
10
11
12
13

14 **Data safety and monitoring board (DSMB)**

15
16
17 To ensure the safety of the study participants and protect the scientific integrity of the trial, a
18
19 three-member independent DSMB together with a study statistician has been established. The
20
21 DSMB will periodically review trial safety and outcome data and make recommendations
22
23 regarding the continuation of the trial based on this information. All serious adverse events
24
25 (SAEs) will be adjudicated by an end point evaluation committee, which reviews
26
27 documentation related to the SAE and decides regarding its potential causal relationship with
28
29 the study drug. Suspected SAEs are also reported as required to the ethics committee of the
30
31 hospital which enrolled the participant, the human research ethics committee of Monash
32
33 University, and to the study sponsor. Treatment will be discontinued if there are SAEs or safety
34
35 concerns relating to the use of the study medicines. Any support necessary to those affected or
36
37 concerned will be provided independent of the study.
38
39
40
41
42
43
44

45 **ETHICS AND DISSEMINATION**

46
47 The trial will be conducted in compliance with the protocol, the principles of Good Clinical
48
49 Practice (GCP), the National Health and Medical Research Council (NHMRC) National
50
51 Statement on Ethical Conduct in Human Research (updated 2015) and the Australian Code for
52
53 the Responsible Conduct of Research (2018). Approval has been obtained from the Human
54
55 Ethics Committees of all the participating hospitals and the University. Written informed
56
57 consent will be obtained from each participant at the time of recruitment.
58
59
60

Both varenicline and NRT have well established safety and efficacy when used appropriately. However, participant safety may still be a concern, especially in combination. Any potential concerns regarding eligibility will be discussed with the treating medical team. Participants in both arms will be closely monitored for any adverse effects.

All identifiable data will be stored securely, in locked filing cabinets and/or password protected computers at the participating hospital sites or at Monash University. Collected data will be de-identified, entered into an electronic database and saved on password-protected computers. Participants will receive their CO breath test result immediately after testing. After data analysis, a summary of findings will be sent to participants who requested this information. The research team will submit study findings to peer-reviewed journals. Any protocol changes will be updated on the ANZ Clinical Trials Registry.

PATIENT AND PUBLIC INVOLVEMENT

This research will be done without patient or public involvement. Patients and the public will not be invited to comment on the study design and will not be consulted to develop patient relevant outcomes, interpret the results or contribute to the writing or editing of study documents for readability or accuracy.

DISCUSSION

Abstinence rates are suboptimal despite the wide availability of various smoking cessation therapies. A significant number of quit attempts result in failure; despite this no new smoking cessation medication has been approved by the Food and Drugs Administration since

1
2
3 varenicline in 2006. Effective combinations of existing smoking cessation therapies are thus
4
5 needed to further boost abstinence rates.
6
7
8
9

10 This is the first multi-centre, placebo-controlled, randomised controlled trial to evaluate the
11
12 efficacy and safety of a combination of varenicline with acute release forms of NRT. This is
13
14 also the first pragmatic trial to explore the effectiveness of this combination treatment in
15
16 achieving long-term abstinence rates among inpatients in Australian hospitals. Varenicline has
17
18 proven to be one of the most effective smoking cessation therapies, however current literature
19
20 suggests that it may not completely attenuate nicotine cravings.(12) This effect could be
21
22 overcome by the addition of an acute release form of NRT.(12, 16) If effective this combination
23
24 treatment may help to further boost abstinence rates and the results of this trial could help guide
25
26 future smoking cessation treatments and guidelines. Smoking is banned in the premises of all
27
28 the participating hospitals. This smoke-free environment will help to promote smoking
29
30 cessation in both the intervention and the control arms of the study.
31
32
33
34
35
36
37

38 Some strengths of the current study include the randomisation of participants to the intervention
39
40 and control arms reducing selection bias and outcome assessment by staff blinded to treatment
41
42 allocation. The multi-centre design of the trial will ensure that the study sample is
43
44 representative of the inpatient smokers who are admitted to Australian public hospitals. It will
45
46 also enable greater generalisability of the study findings. Furthermore, biochemical verification
47
48 of abstinence used in this trial will enable us to make accurate inferences regarding the
49
50 effectiveness of the intervention. According to standard practices, public hospitals in Australia
51
52 offer NRT to inpatient smokers on admission to help them to abide to the hospital's smoke-
53
54 free policy.(42) As a result, some participants may already be using NRT (e.g. patch) when
55
56 they are recruited. This may affect the participant's initial response to the study medication and
57
58
59
60

26

would be one of the potential limitations of this study. Use of NRT after admission to the hospital will be captured and adjusted for in analysis.

TRIAL STATUS

This trial is registered with the Australia and New Zealand Clinical Trials Registry (ACTRN12618001792213). Approval will be sought from the Human Research Ethics Committees of all the participating hospitals and Monash University.

AUTHORS' CONTRIBUTIONS

JG conceived the research idea and developed it with input from other chief investigators, MA, BB, MD, BS, AW and secured research funding. The CIs developed the study in collaboration with GW, SK, OR and AV. RKG is a PhD scholar under the supervision of JG, MA and BB coordinating all the project activities. All the investigators (RKG, MA, BB, GW, MD, BS, AV, AW, SK, DT, AM, RG, EP, JP, DM, LC, ZK, OR, PL, JG) contributed to all phases of the protocol development and finalisation of the manuscript. All authors have reviewed this manuscript and have approved the final protocol.

FUNDING

This study is supported by the Global Research Awards for Nicotine Dependence 2017 (reference number WI231511), an independently-reviewed competitive grants program supported by Pfizer.

COMPETING INTERESTS

Michael Abramson, Billie Bonevski and Johnson George have held investigator-initiated grants from Boehringer Ingelheim (BI) Pty Ltd for an unrelated project. Michael Abramson

27

1
2
3 has also received assistance with conference attendance and conducted an unrelated
4 consultancy for Sanofi. He has also received a speaker's fee from GSK. Johnson George has
5 received honorarium from GSK and Pfizer for consultancy and educational grants for unrelated
6 projects.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. Weiland T, Jelinek GA, Taylor SE, Taylor DM. Tobacco smoking by adult emergency department patients in Australia: a point-prevalence study. *Public Health Res Pract.* 2016;26(3)
2. Drope J, Schluger N, Zachary C, Drope J, Hamill S, Islami F, et al. *The Tobacco Atlas.* Atlanta: American Cancer Society and Vital Strategies; 2018.
3. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. *Cochrane Database Syst Rev.* 2013(5):CD009329.
4. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane Database Syst Rev.* 2016(5):CD006103.
5. Jimenez-Ruiz C, Berlin I, Hering T. Varenicline: a novel pharmacotherapy for smoking cessation. *Drugs.* 2009;69(10):1319-38
6. Wadgave U, Nagesh L. Nicotine Replacement Therapy: An Overview. *Int J Health Sci (Qassim).* 2016;10(3):425-35
7. Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. *Annu Rev Pharmacol Toxicol.* 2009;49:57-71
8. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. *Cochrane Database Syst Rev.* 2018(5):CD000146.
9. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. *Nicotine Tob Res.* 2012;14(3):343-50
10. Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. *Clin Ther.* 2011;33(4):465-77
11. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. *Circulation.* 2016;133(1):21-30
12. Berg KM, Jorenby DE, Baker TB, Fiore MC. Triple smoking cessation therapy with varenicline, nicotine patch and nicotine lozenge: a pilot study to assess tolerability, satisfaction, and end-of-treatment quit rates. *J Smok Cessat.* 2018;13(3):145-53
13. Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer? *Drugs.* 2010;70(6):643-50
14. Cinciripini PM, Minnix JA, Green CE, Robinson JD, Engelmann JM, Versace F, et al. An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. *Addiction.* 2018
15. Thomas D, Farrell M, McRobbie H, Tutka P, Petrie D, West R, et al. The effectiveness, safety and cost-effectiveness of cytisine versus varenicline for smoking cessation in an Australian population: a study protocol for a randomized controlled non-inferiority trial. *Addiction.* 2019;114(5):923-33
16. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. *BMC Med.* 2014;12:172
17. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. *Jama.* 2014;312(2):155-61

18. Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR. Combination therapy of varenicline with nicotine replacement therapy is better than varenicline alone: a systematic review and meta-analysis of randomized controlled trials. *BMC Public Health*. 2015;15:689
19. Ray LA, Lunny K, Bujarski S, Moallem N, Krull JL, Miotto K. The effects of varenicline on stress-induced and cue-induced craving for cigarettes. *Drug Alcohol Depend*. 2013;131(1-2):136-42
20. Grace C. 15.7 Legislation to ban smoking in public spaces. Melbourne: Cancer Council Victoria; 2016 [updated October 2016. Available from: <http://www.tobaccoaustralia.org.au/chapter-15-smokefree-environment/15-7-legislation>.
21. Pelletier JH, Strout TD, Baumann MR. A systematic review of smoking cessation interventions in the emergency setting. *Am J Emerg Med*. 2014;32(7):713-24
22. Murray RL, Leonardi-Bee J, Marsh J, Jayes L, Li J, Parrott S, et al. Systematic identification and treatment of smokers by hospital based cessation practitioners in a secondary care setting: cluster randomised controlled trial. *BMJ*. 2013;347:f4004
23. Rigotti NA, Munafò MR, Stead LF. Smoking cessation interventions for hospitalized smokers: a systematic review. *Arch Intern Med*. 2008;168(18):1950-60
24. Mohiuddin SM, Mooss AN, Hunter CB, Grollmes TL, Cloutier DA, Hilleman DE. Intensive smoking cessation intervention reduces mortality in high-risk smokers with cardiovascular disease. *Chest*. 2007;131(2):446-52
25. Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalised patients. *Cochrane Database Syst Rev*. 2012;5(5):CD001837.
26. Mendelsohn C. Managing nicotine dependence in NSW hospitals under the Smoke-free Health Care Policy. *Public Health Res Pract*. 2015;25(3):e2531533
27. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *Jama*. 2006;296(1):47-55
28. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *Jama*. 2006;296(1):56-63
29. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *Jama*. 2006;296(1):64-71
30. Pfizer. Product information Champix®(varenicline as tartrate). [updated 2013. Available from: http://www.pfizer.com.au/sites/g/files/g10005016/f/201311/PI_Champix_244.pdf.
31. Perrigo Australia. Australian product information - Nicotinell (Nicotine) 2mg and 4mg lozenges [updated 2018. Available from: <https://www.nicotinell.com.au/wp-content/uploads/2019/11/Nicotine-2-and-4mg-Lozenges-PI.pdf>.
32. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. *Addiction*. 2005;100(3):299-303
33. Borland R, Yong HH, O'Connor RJ, Hyland A, Thompson ME. The reliability and predictive validity of the Heaviness of Smoking Index and its two components: findings from the International Tobacco Control Four Country study. *Nicotine Tob Res*. 2010;12 Suppl:S45-50
34. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606-13
35. West R, Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. *Psychopharmacology (Berl)*. 2004;177(1-2):195-9

- 1
2
3 36. George J, Mackinnon A, Kong DC, Stewart K. Development and validation of the
4 Beliefs and Behaviour Questionnaire (BBQ). *Patient Educ Couns*. 2006;64(1-3):50-60
5
6 37. Benowitz NL, Bernert JT, Foulds J, Hecht SS, Jacob P, Jarvis MJ, et al. Biochemical
7 Verification of Tobacco Use and Abstinence: 2019 Update. *Nicotine Tob Res*.
8 2020;22(7):1086-97
9
10 38. Perkins KA, Karelitz JL, Jao NC. Optimal carbon monoxide criteria to confirm 24-hr
11 smoking abstinence. *Nicotine Tob Res*. 2013;15(5):978-82
12
13 39. Thomas D, Abramson MJ, Bonevski B, Taylor S, Poole SG, Paul E, et al. Integrating
14 smoking cessation into routine care in hospitals--a randomized controlled trial. *Addiction*.
15 2016;111(4):714-23
16
17 40. Jackson SE, McGowan JA, Ubhi HK, Proudfoot H, Shahab L, Brown J, et al. Modelling
18 continuous abstinence rates over time from clinical trials of pharmacological interventions for
19 smoking cessation. *Addiction*. 2019;114(5):787-97
20
21 41. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for
22 estimating the probability of adverse drug reactions. *Clin Pharmacol Ther*. 1981;30(2):239-45
23
24 42. Mendelsohn C. Managing nicotine dependence in NSW hospitals under the Smoke-free
25 Health Care Policy. *Public Health Res Pract*. 2015
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. *Ann Intern Med.* 2013;158(3):200-207

	Reporting Item	Page Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1

1	Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	4 & 25
2				
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial Registration Data Set	n/a
7				
8	data set			
9				
10				
11				
12	Protocol version	#3	Date and version identifier	1
13				
14				
15	Funding	#4	Sources and types of financial, material, and other support	26
16				
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol contributors	26
21				
22	responsibilities:			
23				
24	contributorship			
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	26
29				
30	responsibilities:			
31				
32	sponsor contact			
33				
34	information			
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	n/a
39				
40	responsibilities:			
41				
42	sponsor and funder			This is an investigator-initiated trial. The study is supported by a grant awarded by the Global Research Awards for Nicotine dependence 2017.
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53				
54				
55				
56				
57				
58	Roles and	#5d	Composition, roles, and responsibilities of	23
59				
60				

responsibilities: the coordinating centre, steering committee,
 committees endpoint adjudication committee, data
 management team, and other individuals or
 groups overseeing the trial, if applicable (see
 Item 21a for data monitoring committee)

Introduction

Background and [#6a](#) Description of research question and 5
 rationale justification for undertaking the trial, including
 summary of relevant studies (published and
 unpublished) examining benefits and harms
 for each intervention

Background and [#6b](#) Explanation for choice of comparators 7
 rationale: choice of
 comparators

Objectives [#7](#) Specific objectives or hypotheses 9

Trial design [#8](#) Description of trial design including type of 9
 trial (eg, parallel group, crossover, factorial,
 single group), allocation ratio, and framework
 (eg, superiority, equivalence, non-inferiority,
 exploratory)

Methods:

Participants,
 interventions, and
 outcomes

1	Study setting	#9	Description of study settings (eg, community	9
2			clinic, academic hospital) and list of	
3			countries where data will be collected.	
4				
5			Reference to where list of study sites can be	
6			obtained	
7				
8				
9				
10				
11				
12				
13	Eligibility criteria	#10	Inclusion and exclusion criteria for	10
14			participants. If applicable, eligibility criteria	
15			for study centres and individuals who will	
16			perform the interventions (eg, surgeons,	
17			psychotherapists)	
18				
19				
20				
21				
22				
23				
24				
25	Interventions:	#11a	Interventions for each group with sufficient	13
26			detail to allow replication, including how and	
27	description		when they will be administered	
28				
29				
30				
31				
32				
33	Interventions:	#11b	Criteria for discontinuing or modifying	20
34			allocated interventions for a given trial	
35	modifications		participant (eg, drug dose change in	
36			response to harms, participant request, or	
37			improving / worsening disease)	
38				
39				
40				
41				
42				
43				
44				
45	Interventions:	#11c	Strategies to improve adherence to	15
46			intervention protocols, and any procedures	
47	adherence		for monitoring adherence (eg, drug tablet	
48			return; laboratory tests)	
49				
50				
51				
52				
53				
54				
55	Interventions:	#11d	Relevant concomitant care and interventions	16 and 18
56			that are permitted or prohibited during the	
57	concomitant care			
58				
59				
60				

1		trial	
2			
3			
4	Outcomes	#12 Primary, secondary, and other outcomes,	18
5		including the specific measurement variable	
6		(eg, systolic blood pressure), analysis metric	
7		(eg, change from baseline, final value, time	
8		to event), method of aggregation (eg,	
9		median, proportion), and time point for each	
10		outcome. Explanation of the clinical	
11		relevance of chosen efficacy and harm	
12		outcomes is strongly recommended	
13			
14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25	Participant timeline	#13 Time schedule of enrolment, interventions	n/a
26		(including any run-ins and washouts),	
27		assessments, and visits for participants. A	
28		schematic diagram is highly recommended	a schematic diagram has
29		(see Figure)	not been provided
30			however the process of
31			recruitment, treatment
32			initiation and follow-ups
33			is clearly detailed in the
34			protocol
35			
36			
37			
38			
39			
40			
41			
42			
43			
44	Sample size	#14 Estimated number of participants needed to	21
45		achieve study objectives and how it was	
46		determined, including clinical and statistical	
47		assumptions supporting any sample size	
48		calculations	
49			
50			
51			
52			
53			
54			
55			
56			
57	Recruitment	#15 Strategies for achieving adequate participant	11
58			
59			
60			

enrolment to reach target sample size

Methods:

Assignment of interventions (for controlled trials)

Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	12
Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	12
Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	12 & 13
Blinding (masking)	#17a	Who will be blinded after assignment to	18

1		interventions (eg, trial participants, care	
2		providers, outcome assessors, data	
3		analysts), and how	
4			
5			
6			
7			
8	Blinding (masking):	#17b If blinded, circumstances under which	18
9			
10	emergency	unblinding is permissible, and procedure for	
11			
12	unblinding	revealing a participant's allocated	
13			
14		intervention during the trial	
15			
16			
17			
18	Methods: Data		
19			
20	collection,		
21			
22	management, and		
23			
24	analysis		
25			
26			
27			
28	Data collection	#18a Plans for assessment and collection of	16
29			
30	plan	outcome, baseline, and other trial data,	
31			
32		including any related processes to promote	
33			
34		data quality (eg, duplicate measurements,	
35			
36		training of assessors) and a description of	
37			
38		study instruments (eg, questionnaires,	
39			
40		laboratory tests) along with their reliability	
41			
42		and validity, if known. Reference to where	
43			
44		data collection forms can be found, if not in	
45			
46		the protocol	
47			
48			
49			
50			
51	Data collection	#18b Plans to promote participant retention and	16 & 21
52			
53	plan: retention	complete follow-up, including list of any	
54			
55		outcome data to be collected for participants	
56			
57		who discontinue or deviate from intervention	
58			
59			
60			

1		protocols	
2			
3			
4	Data management	#19 Plans for data entry, coding, security, and	24
5		storage, including any related processes to	
6		promote data quality (eg, double data entry;	
7		range checks for data values). Reference to	
8		where details of data management	
9		procedures can be found, if not in the	
10		protocol	
11			
12			
13			
14			
15			
16			
17			
18			
19			
20	Statistics:	#20a Statistical methods for analysing primary and	21
21		secondary outcomes. Reference to where	
22	outcomes	other details of the statistical analysis plan	
23		can be found, if not in the protocol	
24			
25			
26			
27			
28			
29			
30	Statistics:	#20b Methods for any additional analyses (eg,	21-22
31		subgroup and adjusted analyses)	
32	additional analyses		
33			
34			
35	Statistics: analysis	#20c Definition of analysis population relating to	21
36		protocol non-adherence (eg, as randomised	
37	population and	analysis), and any statistical methods to	
38	missing data	handle missing data (eg, multiple imputation)	
39			
40			
41			
42			
43			
44			
45	Methods:		
46			
47	Monitoring		
48			
49			
50			
51	Data monitoring:	#21a Composition of data monitoring committee	21
52		(DMC); summary of its role and reporting	
53	formal committee	structure; statement of whether it is	
54		independent from the sponsor and	
55			
56			
57			
58			
59			
60			

1		competing interests; and reference to where	
2		further details about its charter can be found,	
3		if not in the protocol. Alternatively, an	
4		explanation of why a DMC is not needed	
5			
6			
7			
8			
9			
10	Data monitoring:	#21b Description of any interim analyses and	23
11			
12	interim analysis	stopping guidelines, including who will have	
13		access to these interim results and make the	
14		final decision to terminate the trial	
15			
16			
17			
18			
19			
20	Harms	#22 Plans for collecting, assessing, reporting,	23
21		and managing solicited and spontaneously	
22		reported adverse events and other	
23		unintended effects of trial interventions or	
24		trial conduct	
25			
26			
27			
28			
29			
30			
31			
32	Auditing	#23 Frequency and procedures for auditing trial	n/a
33		conduct, if any, and whether the process will	
34		be independent from investigators and the	
35		sponsor	
36			
37			
38			
39			
40			
41			
42	Ethics and		
43	dissemination		
44			
45			
46			
47	Research ethics	#24 Plans for seeking research ethics committee	23
48		/ institutional review board (REC / IRB)	
49	approval	approval	
50			
51			
52			
53			
54			
55	Protocol	#25 Plans for communicating important protocol	23
56		modifications (eg, changes to eligibility	
57	amendments		
58			
59			
60			

		criteria, outcomes, analyses) to relevant	
		parties (eg, investigators, REC / IRBs, trial	
		participants, trial registries, journals,	
		regulators)	
10	Consent or assent	#26a Who will obtain informed consent or assent	11
11		from potential trial participants or authorised	
12		surrogates, and how (see Item 32)	
18	Consent or assent:	#26b Additional consent provisions for collection	n/a
19	ancillary studies	and use of participant data and biological	
20		specimens in ancillary studies, if applicable	
25	Confidentiality	#27 How personal information about potential	24
26		and enrolled participants will be collected,	
27		shared, and maintained in order to protect	
28		confidentiality before, during, and after the	
29		trial	
38	Declaration of	#28 Financial and other competing interests for	26
39	interests	principal investigators for the overall trial and	
40		each study site	
45	Data access	#29 Statement of who will have access to the	n/a
46		final trial dataset, and disclosure of	
47		contractual agreements that limit such	
48		access for investigators	
55	Ancillary and post	#30 Provisions, if any, for ancillary and post-trial	20
56	trial care	care, and for compensation to those who	

1			suffer harm from trial participation	
2				
3				
4	Dissemination	#31a	Plans for investigators and sponsor to	23
5				
6	policy: trial results		communicate trial results to participants,	
7				
8			healthcare professionals, the public, and	
9				
10			other relevant groups (eg, via publication,	
11				
12			reporting in results databases, or other data	
13				
14			sharing arrangements), including any	
15				
16			publication restrictions	
17				
18				
19				
20	Dissemination	#31b	Authorship eligibility guidelines and any	n/a
21				
22	policy: authorship		intended use of professional writers	
23				
24				
25	Dissemination	#31c	Plans, if any, for granting public access to	n/a
26				
27	policy: reproducible		the full protocol, participant-level dataset,	
28				
29	research		and statistical code	
30				
31				
32				
33	Appendices			
34				
35				
36	Informed consent	#32	Model consent form and other related	n/a
37				
38	materials		documentation given to participants and	
39				
40			authorised surrogates	
41				
42				
43				
44	Biological	#33	Plans for collection, laboratory evaluation,	n/a
45				
46	specimens		and storage of biological specimens for	
47				
48			genetic or molecular analysis in the current	
49				
50			trial and for future use in ancillary studies, if	
51				
52			applicable	
53				
54				
55				
56				
57				
58				
59				
60				

1 None The SPIRIT checklist is distributed under the terms of the Creative Commons Attribution
2 License CC-BY-ND 3.0. This checklist can be completed online using <https://www.goodreports.org/>, a
3 tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60